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Abstract
Abstract
Background
Pregnancy-specific glycoproteins (PSGs) are highly glycosylated secreted proteins encoded
by multi-gene families in some placental mammals. They are carcinoembryonic antigen
(CEA) family and immunoglobulin (Ig) superfamily members. In humans they are
composed of one N-terminal immunoglobulin variable (IgV)-type domain (N) and two or
three immunoglobulin constant (IgC)-type domains (A1 and/or A2 and B2) with a short
C-terminal sequence. PSGs are immunomodulatory, and have been demonstrated to
possess anti-platelet and pro-angiogenic properties. Low serum levels of these proteins
have been correlated with adverse pregnancy outcomes. Following implantation of the
human embryo, PSGs are secreted by the syncytiotrophoblast (STB) and are reported to
be detected at 200-400 µg/ml in the maternal serum at term. The N-domains of many of
the human PSGs are sufficient to mediate their induction of cytokines as well as their anti-
thrombotic function. Motifs representing predicted N-glycosylation sites and a conserved
predicted integrin binding Arginine-Glycine-Aspartic acid (RGD)-like tri-peptide have been
determined to be unnecessary for cytokine release, anti-platelet or angiogenic functions
of PSG1. To date mouse Psgs have been shown to bind differentially to tetraspanin CD9
and both mouse and human PSGs have been shown to have a broad affinity for cell surface
heperan sulphate proteoglycan (HSPG).
Objectives
The research within this thesis had goals within three areas: 1). To attempt to
replicate previously reported cytokine responses to PSG-treatment of immune cells and
subsequently to investigate functionally important amino acids within PSG1. It was further
aimed to examine the signalling underpinning the immunomodulatory functions of this
hormone through small molecule inhibitors and determination of status of important
components of key immune signalling pathways. 2). To determine whether candidate
receptor, integrin αVβ3, was a binding partner for PSG1 and to investigate whether PSG1
possessed functionality in a leukocyte-endothelial interaction assay. 3). To determine
whether proteins generated from recently identified putative PSG genes in the horse shared
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functional properties with PSGs from other species.
Outcomes
1). Sequential domain deletion of PSG1 showed that multiple domains possess TGF-
β1 induction activity from a THP-1 monocytic cell line assay. A conserved RGD-like tri-
peptide was investigated for functional importance in the PSG1N construct and confirmed
to not be necessary for TGF-β1 release by this domain of PSG1. Deletion of N-domain N-
linked glycosylation sites through an asparagine to aspartic acid (N→D) mutation had no
effect on TGF-β1 release. It was demonstrated that loss of glycosylation sites negatively
affected PSG1N expression and secretion with the most dramatic effect caused by deletion
of the most N-terminal glycosylation site in PSG1N. Introduction of this site into a novel
PSG9N construct rescued protein expression highlighting the contribution glycosyation
makes to protein expression. The TGF-β1 response was subsequently found to be due to
contamination of the purified recombinant proteins with latent TGF-β1 and once removed
no TGF-β1 release could be detected in response to PSG1. The ability of PSGs to attenuate
LPS-induced tumour necrosis factor-α (TNF-α) and interleukin (IL)-6 was found, through
use of small molecule inhibitors, to be independant of cAMP-dependant PKA and TGF-β1
signalling. 2). Integrin αVβ3 was identified as a novel PSG1 receptor mediating an as yet
unknown function. Preliminary investigations into a role for PSGs as inhibitors of leukocyte
endothelial interactions showed no effect by PSG1. 3). Horse PSG protein, CEACAM49,
was shown to be similarly contaminated by latent TGF-β1 particle and once removed did
not demonstrate TGF-β1 release from two previously reported PSG-responsive cell types.
Interestingly horse PSG did show anti-platelet properties through inhibition of the platelet-
fibrinogen interaction as previously published for mouse and human PSGs.
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“I’ve been thinking Hobbes”
“On a weekend?”
“Well, it wasn’t on purpose”
Calvin and Hobbes
- Bill Watterson
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Chapter 1
Introduction
1.1 The Placenta
1.1.1 Structure and Function
The placenta is a complex and dynamic organ. It functions to provide physiological support
to the growth of the fetus by facilitating gas and nutrient exchange and mediating the
interactions between the mother and the fetus through pregnancy to parturition. Critically,
it provides a barrier to prevent direct exposure of the semi-allogenic fetus to the maternal
immune system. Interestingly, the placenta, in the relatively short period since it arose in
vertebrate evolution (approximately 100 million years ago (MYA)), developed significant
diversity among placental mammals in terms of structure, cellular differentiation and
mechanisms of endocrine function [1]. In humans and rodents, a fully developed placenta
is composed of three distinct layers. The outer layer or decidua basalis, is composed of the
uterine decidual tissues, including the maternal spiral arteries, which deliver oxygenated
maternal blood to the fetus. The middle layer attaches the placenta to the uterus and
contains fetoplacental cells derived from the outer cell mass of the developing embryo,
called trophoblasts. These cells invade the uterine wall and surrounding blood vessels
co-opting them for the survival of the fetus. The final layer contains highly branched
villous structures of fetal origin, that are bathed in maternal blood and it is here that
the physiological processes that support the fetus are carried out. Broadly, placentas are
classified based on the nature of the materno-fetal interface, ie. the number of tissues
1
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separating the blood supplies of the mother and the fetus. These are haemochorial,
endotheliochorial and epitheliochorial.
In haemochorial placentation, as described for the human and rodent, and unlike in the
other two placental types, there is direct exposure of the semi-allogenic fetal component of
the placenta to the maternal blood supply. While extremely efficient for gas, nutrient and
waste exchange it creates physiological complications for maternal haemostasis and also
for maintenance of the feto-maternal immunological network during pregnancy [2]. This
type of placentation is found in higher order primates and rodents as well as rabbits. In
endotheliochorial placentation the fetal epithelium encloses the maternal blood vessels.
This type of placentation is common in carnivores but there is evidence of this type of
placentation in orders from all four clades of eutherian mammals indicating that they have
recently been found to be more widespread and diversified than originally believed [3].
Interestingly, haemochorial placentas of some species of bats and sciuromorph rodents can
be seen to go through a transient endotheliochorial stage before establishment of the full
haemochorial materno-fetal interface [3]. In epitheliochorial placentation the maternal
and fetal epithelia appose each other. This type of placentation is found in ruminants
and hoofed mammals as well as cetaceans and in the strepsirrhine primates such as the
lorises and the lemurs. A summary table outlining the orders of mammals in 4 superordinal
clades with examples and placental type indicated can be found in [4]. All three interhaemal
barriers are represented schematically in Figure1.1
Placentas are further classified based on their shape; discoid, bi-discoid, cotyledonary,
diffuse and zonary; and further still based on the nature of the materno-fetal interdigitation
which can be: folded, lamellar, trabecular, villous or labyrinthine [4]. Understanding the
biology of placentas of different species is becoming more and more relevant. Investigations
into the cloning, by somatic cell nuclear transfer, of economically important species
such as cattle, give an insight into complications that can arise and potentially only be
solved through in-depth investigations of placental biology, which is seen to frequently
be central to the onset of pathologies [5]. Interestingly, it was recently demonstrated
that gene expression in post-implantation embryos generated by somatic cell nuclear
transfer correlated with donor cell type, but only for the embryonic tissue and not the
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Epitheliochorial
Endotheliochorial
Haemochorial
Endothelium
Red Blood Cells
Syncytiotrophoblast
Cytotrophoblast
Stroma
Maternal epithelium
Fetal
Maternal
Fetal
Maternal
Fetal
Maternal
Figure 1.1: Types of interhaemal barriers present in placentas
The three main interhaemal barriers found in eutherian mammals are represented
diagramatically showing the different types of interaction that occur between fetal and
maternal tissues across mammalian placentas.
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extra embryonic tissues [6]. This study demonstrates that somatic cell nuclear transfer
effects on extraembryonic tissue gene expression were not ameliorated based on donor cell
choice and reaffirms that the difficulties inherent in this technique are still far from being
addressed.
1.1.2 Evolution
With the onset of the genomic era significant advances have been made in the field of
phylogenetics that have furthered our understanding of animal evolution. Recent efforts
by Song et al. have utilized phylogenetics and a multispecies coalescent model to refine
placental mammal phylogeny [7]. The resultant updated evolutionary relationship within
mammalian species with specific focus on the eutheria, or true placental mammals, is
reproduced in Figure1.2. It has been claimed that there is considerable adaptive pressure
for the development or retention of the haemochorial chorioallantoic structure of placentas
[8]. Wildman and colleages, based on phylogenetic and statistical analysis of molecular and
morphologic data, claim that the earliest common therian ancestor may have possessed
a haemochorial placental interface with discoid shape and labyrinthine materno-fetal
interdigitaion [9]. It has been further argued, again using phylogenetics, that highly invasive
haemachorial placentation, as found in humans, is, at least, a very early evolutionary
adaptation found in the most ancient ancestors of placental mammals [10]. There is no
clear picture of what the placental type of the last common ancestor to therian mammals
may have been. Difficulties arising from the lack of agreement with regards to the rooting
of mammalian trees, which would inform decisions in this area, affect the determination of
this phenotype [11, 12]. While it was held that epitheliochorial placentation was an ancient
state based on its presence in what were formerly considered ’primitive’ animals, consensus
appears to have shifted towards it being a derived state that has evolved once in the the
common ancestor of pangolins, horses, even-toed ungulates, and whales; as well as once in
the primate lineage[11, 12, 13, 14].
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1.1.3 The Trophoblast
The process of implantation is a dynamic and complex process that is mediated by a
reciprocal sequence of changes in both the embryo and the maternal uterine epithelial
surfaces that allow for intial weak interaction through the uterine glycocalyx followed by
a subsequent shift to firmer interactions [15]. The mechanisms that underpin this are
still poorly understood but initial interactions are believed to be dependant on mucins,
a family of glyco-proteins in the apical glycocalyx [16]. The fundamental importance of
these processes is underlined by the fact that errors in them can have adverse effects
that perpetuate throughout pregnancy Figure1.3. Trophectoderm is the first cell type to
be differentiated from the developing embryo and it plays critical roles in implantation
and the development of the placenta [17]. Once the embryo has been anchored to the
cell wall, the development of the extra embryonic cell lineages from the trophectoderm
begins, an important step that leads to the establishment of the materno-fetal interface
[18]. The trophoblast is an epithelial-like cell type, derived from the trophectoderm, that
mediates much of the angiogenic and immune modulations of the maternal physiology
that are necessary for the generation of the placenta [19, 20]. The outline of early human
embryogenesis, illustrating when the trophoblast lineage is determined, as well as days for
hatching and implantation, is illustrated in Figure1.4A.
In humans the trophoblast has three distinct types that are generated during placentation.
The first layer is the villous cytotrophoblast (vCTB), which is considered the progenitor
of the other types. These are located within the villous structures of the placenta. It
forms a monolayer of cells seperated from the fetal stroma by a basement membrane. The
vCTB then undergo differentiation into two lineages represented by the fusion lineage or
invasive lineages. The fusion route yields the syncytiotrophoblast (STB). This is a multi-
nucleated cell layer that covers the villous structures of the placenta. It is the main site
of physiological exchange between the maternal blood supply and the fetal component
of the placenta. The invasive lineages forms the extra-villous trophoblast (EVT). These
are highly invasive trophoblasts that form the anchoring structures of the anchoring villi,
attaching the villi to the maternal decidua. Invasion of the maternal decidua and spiral
arteries gives rise to interstitial and endovascular trophoblasts. These initially block the
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maternal spiral arteries until weeks 10-12 when bloodflow into the interstitial space begins
[22]. Oxygen tension regulates trophoblast proliferation and invasion into the spiral arteries,
the literature surrounding this is reviewed in [18]. In contrast to the previous hypothesis
that endovascular trophoblasts migrate against flow, it has recently been demonstrated that
high shear cause trophoblast migration in the direction of flow [23]. It is argued that the low
shear induced by arterial plugging in the early stages of placentation generates a low shear
favourable to endovascular migration.
Endovascular and interstitial trophoblasts invade as deep as the maternal myometrium.
A recent review of Wnt signalling in trophoblasts highlighted the important role it plays
in the formation of the invasive EVT phenotype with significant nuclear accumulation of
β-catenin associated with invasive EVT development [24]. Interestingly, it has also been
recently demonstrated that TGF-β1 mediated inhibition of trophoblast invasive capabilities
is mechanistically mediated by Snail down-regulation of VE-Cadherin, which is a known
interacting partner of β-catenin [25]. In addition, further characterisation of the EVT
phenotype has shown that A Disintegrin and Metalloproteinase 12 (ADAM12) is found in
anchoring as well as highly invasive decidual EVT and was demonstrated to play a critical
role in their invasive phenotype [26]. Figure1.4(B) shows the process of the invasion of the
maternal spiral arteries in early placentation.
As a result of obvious ethical constraints, research in this area of human biology is
limited to what progress can be made in human embryos and tissue explants in vitro
and extrapolations that can be made from model organisms such as the mouse [27, 28].
A comparative systems biology approach investigating protein and mRNA expression
data between microdissected vascular exchange regions of both human and mouse term
placentas found that of 7000 ortholog genes detected, over 70% were co-expressed in both
species [29]. In addition, more than 80% of genes known to cause placental pathologies
in the mouse are co-expressed in the human [29]. Thus while there are anatomical and
developmental differences between human and mouse placentation, the usefulness of the
mouse as a model system for studying early placental development is significant. Progress
in this area, while elucidating fundamental areas of biological interest, also has clinical
applications. Developments could assist in vitro fertilization technologies as well as the
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development of human embryonic and pluripotent stem cells for regenerative therapies.
A key driver which underpins many of the physiological differences observed between
placental forms of different species, and even within similar placental forms between
very closely related species, such as the rat and the mouse, is the degree and pattern
of trophoblast invasion of maternal tissues [30]. Humans, chimpanzees and gorillas
possess highly invasive trophoblasts that travel deep into the maternal decidua reaching
as far as the myometrium[31, 32, 33]. Failure of this phenotype leads to poor maternal
arterial remodelling and results in pre-eclampsia. This disease, which affects almost 4% of
pregnancies, was formerly believed to be specific to humans [34]. However, Anthony Carter
points out that evidence has been accumulating to suggest that it is a trait shared in most
higher primates with this type of invasive placentation [31, 35, 36, 37]. In contrast, murine
implantation and trophoblast invasion are far more restricted. The depth of invasion of
the trophoblast in humans and apes has been argued to be necessary to accommodate the
larger oxygen requirements of the greater brain size found in these species however it has
been pointed out that mammals like the dolphin show nearly as large brain development
but possess epitheliochorial placentation [38]. It has been suggested that the evolution of
the invasive haemachorial phenotype has been driven by maternal-fetal conflict [38, 39].
1.1.4 Maternal-fetal cross-talk and immune modulation in pregnancy
Transcriptomic analysis has revealed that there is expression of reciprocal ligands and
receptors between trophectoderm and the endometrium during the implantation window
[40]. Following implantation, the trophoblasts are the sole semi-allogenic cell types
generating an immune response from the mother as they represent the portion of the
fetal component of the placenta in contact with the maternal tissues. It is long known
that there is significant leukocyte invasion of the decidua during placentation and it has
been demonstrated that there is an enrichment of decidual leukocytes at the trophoblast
invasion front [41]. The persistence of the trophoblasts in this context is interesting and
points to factors inherent in the trophoblast that suppress or modify the functions of
the maternal immune system. Studies on horse trophoblast have contributed greatly to
our understanding of the maternal immune response to the trophoblast [42]. Analysis of
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lymphocyte subpopulations from peripheral blood and the trophoblastic structures of the
horse, the endometrial cups, show a T regulatory cell (Tr e g cell) bias in the cup lymphocyte
populations [43]. Furthermore, ectopically transplanted chorionic girdle cells were found
to survive for a time period similar to that of the endometrial cups in the mare[44].
Haemochorial placentation presents
a notably complex situation for maternal immunostasis as the trophoblasts are in direct
contact with the maternal immune system, even more so in situations of deep trophoblast
invasion. A review of the literature surrounding the potential immunological underpinnings
of pregnancy disorders in species which evolved deep trophoblast invasion argues that an
interesting parallel exists in species with deep trophoblast invasion and the evolution of the
major histo-compatability complex (MHC) class I type antigens and their receptors [31]. In
species where deep invasion is seen, a polymorphic pattern has evolved in the MHC class I
type antigens. Evolution of this polymorphic trait may have been required for deep invasion
but has the consequence that certain genotypes for maternal killer immunoglobulin-like
receptors (KIRs) and fetal genotype for MHC class I antigens may be incompatible and
result in increased risk of pregnancy disorders such as preeclampsia. Genetic studies have
indicated that KIR expressed on dNK cells can contribute to preeclampsia [45]. This is
mechanistically supported by the fact that interactions between invading trophoblasts and
the maternal decidual natural killer cells are a key determinant of the invasive capacity of
the trophoblast and alterations in the amount of dNK cells can contribute to preeclapmsia
[46, 45].
As well as local immune suppression, pregnancy is characterised by a general type 2 helper
T cell (Th 2) type polarisation of the systemic immune system which is often associated with
amelioration of autoimmune conditions such as multiple sclerosis [47]. It has been argued
for a modification of the simple Th1/Th2 paradigm to a Th1/Th2/Th17 and regulatory T cell
paradigm for pregnancy that is more reflective of the multi-polarity of the T cell responses
found in biology [48]. Fetal HLA-C competent T cells are present in the decidua, however,
while there is activation of these cells, there is no detrimental effect on pregnancy [49].
Thus, while an adaptive immune response is possible, it is not realised in the decidual
environment. The mechanism for this remains elusive but it is believed Tr e g cells could
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play an important role.
Not only do factors inherent to the trophoblast alter maternal immune function, conversely,
decidual factors can also alter trophoblast function. It has been shown that decidually
secreted factors alter the composition of invasive trophoblast membrane and secreted
proteins in vitro [50]. Furthermore, plasma from women with preeclampsia has been shown
to inhibit invasion of trophoblast cells [51]. in addition, evidence is accumulating that
maternal circulating blood cells make positive contributions to implantation and vascular
remodelling during pregnancy in co-operation with the endocrine system [52]. Thus there
is broad maternal-fetal cross talk during pregnancy.
1.1.5 Placentally Expressed Genes
One means of trying to elucidate placental evolution is to examine the evolution and
function of placenta specific genes. Rawn et al. conclude in a lengthy review of the literature
concerning the evolution and function of placenta specific genes, that a major limitation
of examining placenta-specific gene product function is that many are species-specific,
making comparative studies difficult [53]. The presence of convergent evolution in diverse
gene families further confounds conclusions on the evolution of these genes. Moreover,
subtle differences in promoter sequences can mean while genes are conserved between
species, they may only be placentally expressed in a subset of species. The authors finally
observe that the number of placenta-specific genes is modest and cannot account for the
diversity of placental form and function among mammalian species [53].
Nonetheless, an interesting observation regarding placentally expressed genes is that some
are members of multi-gene families [54, 55]. Gene duplication and conversion are known
to be critical to the evolution of gene families [56, 57]. Moreover, it is known that some
of the most rapidly evolving genes have roles in immune responses and reproductive
processes [58]. Furthermore, antagonism between maternal and fetal genes, in the placenta,
that govern maternal resource allocation and investment in pregnancy is hypothesised
to represent an environment of evolutionary conflict and, as such, a selective pressure
potentially driving evolution of these genes [39, 59, 60]. The CEA gene family, a sub
Pregnancy Specific Glycoprotein Function,
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group of the Ig superfamily, have roles in both reproduction and immune function. Of
particular interest to scientists interested in placental evolution are the PSGs which together
with the CEA-related cell adhesion molecules (CEACAMs) make up the CEA family. To
date, these are found only in haemachorial placental mammals (rodents, primates and
bats) with one recently observed exception being the horse [58]. Understanding the
function and evolution of PSGs as well as their role in the haemochorial phenotype
and establishment/maintenance of pregnancy may provide insight into the evolution of
placentas and also the selective forces that drive this.
1.2 The CEA family: CEACAMS and PSGs
1.2.1 The Carcinoembryonic Antigen (CEA) family
CEA was identified in the 1960s as a tumour associated protein in human colorectal
carcinoma [61]. More CEA-like proteins were discovered and the cloning of CEA cDNA
sequence allowed the identification of paralogues which led to the designation of a CEA
family of proteins [62, 63, 64, 65, 66]. Members of the family are encoded by a specific
gene structure which is a determining factor in their assignment to the family [65, 67, 68].
CEA proteins are members of the Ig superfamily. In humans, the CEA cluster of genes is
encoded on chromosome 19q13.1-19q13.2 [69, 70, 71]. The first exon encodes the initial
residues of a 34/35 amino acid signal peptide that targets the molecules to the secretory
pathway. The second exon encodes the remainder of this sequence and also the N-terminal
IgV-type domain common to all mature CEA family members.The remaining exons encode
different numbers of IgC-type domains. The CEA family is composed of two subfamilies,
the widely expressed CEACAMs, and the PSGs which show placenta-specific expression.
The nomenclature associated with the CEA family has reviewed [72]; the original CEA is
now CEACAM5; nonspecific cross-reacting antigen (NCA) or CD66c is now CEACAM6 and
biliary glycoprotein (Bgp), later classified as CD66a is now CEACAM1.
One of the most striking differences between the CEACAMs and the PSGs, apart from
their expression patterns, is the lack of a C-terminal membrane targeting component in
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PSGs. In CEACAMs a hydrophobic transmembrane sequence or glycophosphatidylinositol
(GPI) anchoring leads them to attach to the cell surface as opposed to the PSGs, which
are all secreted. In CEA members, the evolution of GPI anchorage from transmembrane
anchored ancestors has been argued to have been a very simple adaptation to give radically
different molecular function to Ig superfamily members during evolution [73]. This mode of
anchorage is found only in primate CEA family members [58]. All CEA members are highly
glycosylated, a modification that can account for between 30-60% of their mass, with the
PSG members showing slightly less glycosylation than the CEACAMs [74]. Figure 1.5 shows
the domain architecture and predicted glycosylation of the human CEA family subgroups.
Resolution of the crystal structure of murine CEACAM1 IgV and IgC type domains as well
as bioinformatic analysis of the CEA family members demonstrated that, structurally, the
arrangement of the beta sheets that make up the Ig domains of the proteins is expected to be
very conserved based on protein sequence similarity between members of the CEA family
[75]. This can be seen from an alignment of the N domain protein sequences of the human
CEA family members [75]. Two interesting characteristics of CEA N domains distinguish
them from similar IgV type domains in other immunoglobulins, that is the presence of a
unique glycan shielded hydophobic patch and the orientation of the CC’ loop of the protein,
which, along with the FG loop, are important for homo and heterophilic interactions as well
as virus attachment [76]. Within CEA family members N/N1 domains, most of the sequence
variation occurs on the C”C’CFG faces of these molecules [75]. These differences reflect the
fact that the C”C’CFG faces of Ig superfamily proteins are frequently used for cell surface
recognition. Variations in this face likely confers unique binding capabilities. Furthermore,
this face of the CEA family members are frequently subverted as pathogen cell surface
receptors reflecting a source of potential selective pressure for alterations to overcome this
[77, 78, 79, 80, 81, 72, 58]. In addition, the expression of CEACAM and PSG in placental
tissues means they could also be subject to selective pressure resulting from maternal-fetal
conflict [58]. The CEA family has recently been shown to be undergoing positive selection
based on their pattern of sequence divergence [82].
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Figure 1.2: Phylogenetics of eutherian mammals
The phylogenetic relationship between the eutherian mammals was further resolved by
Song and colleagues and their data is reproduced here [7]. (Copyright National Academy
of Sciences)
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Figure 1.4: Human embryogenesis and trophoblast development
(A) Day 1 to day 9 in human embryo development showing first stage of differentiation
occurring around day 4 giving rise to the trophoblast progenitor cells and inner cell mass.
The trophoblast cells subsequently mediate implantation around day 7 before ultimately
giving rise to the placenta (http://en.wikipedia.org/wiki/User:Zephyris). (B) Trophoblast
differentiation gives rise to synctiotrophblast as well as the extravillous trophoblast lineages
which invade and modify the maternal spiral arteries through both interstitial and
endovascular routes [18].
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1.2.2 CEACAM Expression and Function
CEA-related cell adhesion molecule (CEACAM) are cell adhesion molecules mediating
homo and heterophilic interactions, with expression in several cell types [83]. Several
CEACAMs contain immunoreceptor tyrosine-based signalling motifs (ITIMs) which are
found in an array of inhibitory molecules known to negatively regulate cell activation
[84]. CEACAM1, the most widely expressed CEACAM, is found in epithelial, endothelial
and a number of immune cells including B cells, T cells, NK cells, dendritic cells,
macrophages and granulocytes [85, 86, 83]. Roles in normal and cancerous tissue
development, angiogenesis, immune function and host pathogen interactions have been
ascribed to CEACAMs [87, 88, 89, 83]. There are 12 human and 15 mouse proteins
(http://www.carcinoembryonic-antigen.de). CEACAM expression is restricted to mammals,
although evidence of their expression has recently been claimed in fish [90, 58]. Five
human CEACAM genes show orthologs in other therian mammals (CEACAM1, CEACAM16,
CEACAM18, CEACAM19, CEACAM20) and are considered the ancient CEACAM gene family
present in the last common therian ancestor [91, 58]. As well as there being 12 human
family members, CEACAM1 has 12 splice variants. Two variants, designated L and S, alter
the cytoplasmic signalling portion of CEACAM1 by inclusion (L) or exclusion (S) of the 7th
exon. This generates CEACAM1 with or without a cytoplasmic ITIM signalling domain. The
mechanism underpinning this process in normal tissues, which is deregulated in cancer
tissues, was recently found to be dependant on cis acting elements within the flanking
introns and exons as well as expression levels of specific rnRNPs [92, 93, 94, 95].
The relevance of CEACAMs to cancer is reflected in the discovery of the original CEA
molecule as a tumour associated protein in 1965 [61]. Their potential roles in this
heterogeneous disease have been studied extensively since. A recent review covered, in
depth, their importance in this field with specific focus on the more widely researched
CEACAM1, CEACAM5 and CEACAM6 [96]. CEACAMs are used widely as biomarkers with
CEACAM5 being utilised to detect colorectal carcinomas and positive lymph node tissues.
CEACAM6 expression has been shown to be higher than CEACAM5 in several cancers and it
may now represent the most specific marker from the family for a number of more agressive
types [97, 98, 96]. CEACAM1, as already outlined, has the widest normal tissue distribution
Pregnancy Specific Glycoprotein Function,
Conservation and Receptor Investigation
16 Ronan T. O’Riordan
1. INTRODUCTION 1.2 The CEA family: CEACAMS and PSGs
of the CEACAMs and deregulation of its splice pattern occurs in transformed tissues [86, 93].
Recent investigations have identified novel splice variants of CEACAM5 and claim they
could improve the prognostic usefulness of this protein marker in gastrointestinal cancers
[99]. Studies on all three of these CEACAMs in A549 lung cancer cells again revealed that
forced deregulation of the CEACAM1-L as being functionally important for undifferentiated
cell growth and malignant transformation, though the L and S ratios were not observed to be
altered endogenously between non-tumour and tumour subpopulations [100]. It was also
demonstrated that alterations in the expression of other CEACAMs may impact on normal
CEACAM1 function and furthermore that the secretion of soluble CEACAM5/6 from these
cells was also identified, representing a potential source of increased serum levels of these
proteins found in lung cancer patients.
More recently, soluble CEACAM5 has been shown to increase proangiogenic endothelial
cell behaviour in vitro as well as tumour microvascularisation in vivo with increased
serum levels being correlated with increased tumour microvascularisation in patients [101].
In addition it has been shown that secreted microvesicles contain CEACAMs and their
composition differs between normal and tumour tissue [102]. These CEACAM1-positive
microvesicles were shown to increase CD3 and CD3/CD28-induced T-cell proliferation.
CEACAM6 also has functional implications for cancer progression. In myeloma, cancer cell
expressed CEACAM6 has been demonstrated recently to neutralise competent cytotoxic T
cells [103]. Moreover it has been demonstrated that silencing of CEACAM6 expression in
cancer cells decreases invasiveness and over-expression increases invasiveness in colorectal
cancer cells [98]. Other CEACAMs also have prognostic potential with CEACAM19 recently
correlated with poor breast cancer prognosis [104]. These data highlight the potential for
CEACAMs to provide increased prognostic power for stratification of patient cancer risk as
well as outlining mechanisms by which acquisition of altered CEACAM expression, both
cellular and soluble, can contribute to the development of metastatic disease.
As well as their role in cancer through both disruption of normal tissue homeostasis
and immune evasion, CEACAMs play an important role in the normal function of the
immune system as well as being exploited by pathogenic bacteria and viruses as cell surface
receptors. Pathogenic bacteria exploit human CEACAMs for adhesion to and entry into
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their host cells. This generates cell specific targets due to the tissue specific expression
of CEACAMs. Neisseria gonorrhoeae exploit epithelially expressed CEACAMs; CEACAM1,
CEACAM5 and CEACAM6 to colonise mucosal tissues. In contrast, host granulocyte
CEACAM3 expression allows for the recognition of N. gonorrhoeae by the innate immune
system [105, 106]. This binding is through Neisserial colony opacity (Opa) proteins, the
type of which can determine whether a patient will develop disseminated disease or not
[107, 108]. There are two mechanisms of CEACAM mediated uptake of N. gonorrheae, lipid
raft and CEACAM3 Src dependent [109]. No homologue exists for CEACAM3 in other species
and this has led some to argue that it has evolved to allow innate immune control of human
specific pathogens [110].
1.2.3 Pregnancy Specific Glycoproteins
PSGs are the most abundant fetal proteins in human maternal blood at term in pregnancy
[111]. They are produced by cells of the trophoblast lineage; syncytiotrophoblast in higher
primates and spongiotrophoblast or giant cells in rodents [112, 113, 68]. The localisation
of the expression of PSGs to the placenta, taken with evidence of the correlation of low
serum PSG levels with poor pregnancy outcomes, specifically diseases characterised by
placental insufficiency, indicates that they may play a fundamental role in the formation,
and maintenance, of the materno-fetal unit [112, 114, 115, 116, 117, 118, 119, 120, 121, 122].
While PSGs were believed to be found solely in haemochorial placental mammals of the
primate and rodent lineages, there is bioinformatic and experimental evidence of candidate
PSG-like genes in the bat and the horse [58]. Two related expressed sequence tags (ESTs)
from equine trophoblast complementary DNA (cDNA) libraries corresponding to secreted
equine CEACAMs lend further evidence to the existence of horse PSG-like genes [58]. PSGs,
like many placental hormones, are found in multi-gene families in all species in which they
are found [54, 58].
The domain architecture of the PSGs are very similar to the CEACAMs, being composed of
one N-terminal IgV type domain (N) followed by a number of IgC type domains (A and B).
However there is a clear pattern of divergence between primate (Fig. 1.6(A)) and rodent (Fig.
1.6(B)) PSG domain architecture with expansion of the IgV type domains within the rodents.
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Rodent PSGs are composed of a series of three or more N domains and a single C-terminal
A domain. There is however a high degree of similarity in the amino acid composition of the
human N and rodent N1 domains. This conservation of general structure (N terminal IgV
type domain) and sequence composition as well the conserved sites of expression imply a
conserved function between primate and rodent PSGs [81]. In addition, the conservation
of RGD and RGD-like motifs on the solvent exposed F-G loop in the human and rodent
PSGs supports a role for these motifs in PSG function [123]. Conversely, the expansion and
diversification of the rodent family may also imply novel functions for rodent Psgs[81].
Pregnancy Specific Glycoprotein Function,
Conservation and Receptor Investigation
19 Ronan T. O’Riordan
1. INTRODUCTION 1.2 The CEA family: CEACAMS and PSGs
PSG1 PSG2 PSG3 PSG4 PSG5 PSG6 PSG7 PSG8 PSG9 PSG11
A
B
Human PSG 
Mouse PSG 
Figure 1.6: Human and mouse PSG domain architecture
(A) Human PSG domain architecture showing conservation of general structure among
family members. (B) Mouse domain architecture showing expansion and diversification
of N domains within the family.
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1.2.4 PSG Expression and Regulation
In contrast to the widely expressed CEACAMs, PSG expression is normally restricted to
the placenta. There is limited evidence of expression of PSG outside the placenta. In the
mouse Psg16 has been reported in the brain [124]. One study examined the expression of
PSG in breast cancer and correlated it with poor prognosis [125]. There is one report of
expression of PSG in haematopoetic cells [126]. Evidence of aberrant expression of PSG9 in
colorectal cancers has also been found [127]. Psg18 has been found expressed in the murine
intestine, demonstrated by in-situ hybridization and with anti-Psg18 polyclonal antibody
against a 16 amino acid carboxy-terminal sequence from Psg18 [128]. The expression was
localised to follicular associated epithelium overlaying Peyers patches where there are high
levels of antigen presenting cells present. Furthermore, recent work has demonstrated that
murine Psg can be detected throughout the gastro-intestinal (GI) tract (Williams, J., PhD
thesis). Moreover, unpublished work from our group has shown that PSG staining can
be detected in the human oesophagus and lower GI tract, sites where mucosal immune
regulation is critical for tissue homeostasis. The presence of PSG at sites of immune
contact in the placenta and the mucosal tissue of the GI tract indicate that PSGs may have
immunoregulatory functions that are common to both these sites in normal biology.
Human PSGs are tightly linked on the long arm of chromosome 19 and their expression is
co-ordinately regulated [129]. PSG can be detected secreted from cultured human embryos
as early as 3-4 days after fertilisation [130]. The expression of PSG is upregulated upon
cytotrophoblast (CTB) syncytialisation, as can be seen from the detection of PSG1, PSG3,
PSG5, PSG7 and PSG9 transcripts in differentiated Jeg-3 human choriocarcinoma cells and
CTBs but not from undifferentiated precursors [131]. In agreement with the believed co-
ordinated regulation of the human PSGs, the promoter sequences show strong homology
between family members [132]. However it has been argued that subtle differences between
promoter sequences could allow for differential expression [133]. Some of the factors that
have been functionally implicated in the regulation of the expression of human and mouse
PSG are summarised in Table 1.1. This clearly indicates that most of the work concerning
PSG regulation has been carried out on human PSG, most notably, PSG5.
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Human PSGs do not possess conventional promoters, but their minimal promoter regions
have been defined as spanning -172 to -34 bp [132, 133, 134]. An SP1 binding site mapped
within this region and SP1 is known to co-express with PSG5 in the placental villous,
notably in the STB layer [135]. All human PSGs contain a putative Retinoic Acid Response
Element (RARE) and Lopez-Diaz et al. confirmed the functionality of this in response
to 9-cis retinoic acid treatment as well as by mutation of PSG5 reporter constructs and
analysis of RXRα binding [136] . Two Kruppel-like factors (KLFs) have been implicated in
PSG regulation; KLF4 and SP1 act synergistically to increase PSG5 expression [137]; KLF6
was also implicated in the regulation of PSG3 and PSG5 [138]. The demonstration of the
response of PSG gene expression to KLFs is interesting in the context of the recent reports of
PSG expression in the GI tract both in normal and disease settings as KLFs play a critical role
in development, regulation and carcinogenesis in these tissues [139]. There is also evidence
to suggest that PSG genes are regulated at the higher order chromatin structure level[140].
Table 1.1: Published Regulators of PSG/Psg expression
Regulator PSG Responsive Cell Lines References
Human
CPBP PSG5 Jeg3 [141]
KLF4 PSG5 Jeg3, HeLa [142, 137]
KLF6 PSG3, PSG5 Jeg3 [142, 138]
SP1 PSG5 Jeg3, HP-A1 [133, 135, 137]
RXR PSG5 Jeg3 [136]
Mouse
XBP1, IRE1a Psg18, Psg28 SM-10, MEF [143]
1.2.5 PSG Function
The importance of PSGs to successful pregnancy is underscored in the already outlined
correlation between low PSG and diseases of placental insufficiency. In addition, it is
recognised that dysfunction of the syncytium, the site where PSGs are synthesised, and
changes in the soluble factors generated there, such as soluble endoglin (sEng), as well
as the anti-fibrinolytic factor plasminogen activator inhibitor-1 (PAI-1), contributes to
preclampsia [144]. Furthermore,it has been observed that the application of anti-PSG
antibodies or vaccination with PSG induces abortion in mice and monkeys, respectively,
and reduces the fertility of non-pregnant monkeys[145, 146]. However, these studies are
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relatively old and there are uncertainties surrounding the quality/specificity of antibodies
utilised. While the exact function of PSGs remain uncertain, a body of literature has
accumulated over the last number of decades examining immunomodulatory, angiogenic
and anti-platelet functions of these hormones.
Thirteen years of published work has shown that PSGs are immunomodulatory and pro-
angiogenic hormones that can directly induce various cytokines from several cell types in a
cross-species reactive manner[147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157]. Table 1.2
outlines the published cytokine responses reported for individual PSGs and the responsive
cell types. The identification of these cytokines as induced by PSGs, and the particular
cell types responsive to PSG treatment represent critical steps in the characterisation of
the fundamental role that PSGs play in the establishment of feto-maternal unit and its
maintenance throughout pregnancy. Many of these cytokines have well documented roles
in the promotion of an immune environment that is accommodating of the semi-allogenic
fetus as well as angiogenic functions.
Table 1.2: Published cytokine responses for PSGs
PSG Cytokines Responsive Cell Types
1
IL-6 [149, 157], IL-10 [149], TGF-β1 [149, 152,
153, 155, 157], VEGF-A [155]
monocytes/macrophages,
dendritic, endothelial,
trophoblastic
6 IL-6 [149], IL-10 [149], TGF-β1 [149] monocytes/macrophages
11 IL-6 [149, 153], IL-10 [149], TGFβ1 [149] monocytes/macrophages
17 IL-6 [153], IL-10 [153], TGF-β1 [153] macrophages
18 IL-10 [148] macrophages
19 TGF-β1 [154] macrophages
22 TGF-β1 [156], VEGF-A [156] dendritic, natural killer
23 TGF-β1 [158] VEGF-A [158]
monocytes/macrophages,
dendritic, endothelial,
trophoblastic
IL-10 expression is up-regulated in the first and second trimesters of pregnancy and lower
in the third concurrent with a gestational age based function for this cytokine, with high
levels required during early to mid gestation and decreasing levels potentially contributing
to parturition[159]. There is also an increase in IL-10 release from uterine lymphocytes
and NK cells compared to peripheral blood mononuclear cells (PBMCs) in response to
LPS [160, 161]. Furthermore IL-10 is lower is placental tissue of women with spontaneous
abortion compared to elective controls [162]. IL-10’s role as a vascular protective agent and
the contribution this could make to pregnancy and prevention of preeclamptic symptoms
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is also recently coming to light as reviewed by [163]. Thus, IL-10 has multifaceted roles in
pregnancy [164].
As can be seen from Table 1.2, TGF-β1 is the most widely documented PSG induced
cytokine. It has well documented roles in the regulation of inflammation and angiogenesis
[165]. TGF-β1 is an interesting cytokine as it is quite extensively post-transcriptionally
regulated. It is a member of the Transforming Growth Factor β1 superfamily. TGFβ1 is
synthesised as a homodimeric proprotein. This is processed intracellularly cleaving the
propetide from the cytokine, however they remain associated and the propeptide and
cytokine are secreted together as a complex as is the case for all TGFβ proteins [166]. This
Small Latency Complex (SLC) containing the cytokine and propeptide or Latency Associated
Protein (LAP) requires activation by proteolytic cleavage before the cytokine can interact
with its receptors [167]. An additional layer of regulation is found in the association between
the SLC and Latent TGF-β1 Binding Proteins (LTBP) which regulate the availability of the
SLC [168]. This triprotein complex is referred to as the Large Latency Complex (LLC). Almost
all publications examining PSG1 induction of TGF-β1 examined total secreted TGF-β1 by
ELISA following acid activation of samples which cleaves the cytkokine from the LAP.
Further work using transient in-vivo expression of PSGs as well as co-culture systems
examined the immunomodulatory effect of PSG1 further. It was demonstrated that
untagged PSG1 produced from a transient vaccinia based expression sytem in HeLa or
J774 cells could up-regulate arginase expression in primary human monocytes and human
and mouse monocyte cell lines as well as suppressing LPS-induced Nitric Oxide (NO)
production [147]. This study also demonstrated that PSG1 altered accessory cell dependant
activity of T-cells both in vivo and in vitro. The observations were further characterised
by Motran et al. where the authors demonstrated that ovalbumin challenged splenic
monocytes from vaccinia PSG1 mice showed a Th 2 polarised pattern of cytokine response
(high IL-4, IL-5 and IL-10, and low interferon (IFN)-γ and IL-2 production) compared to
splenic monocytes from control mice [152]. It was demonstrated that this response could
be mediated by IL-10, as IL-10 blocking antibodies rescued the induction of IL-2 and IFN-
γ in some situations of stimulation. IL-10 block also rescued the suppression of splenic
monocyte proliferation observed in monocytes isolated from vacPSG1 mice. Furthermore,
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this study confirmed the alternative activation state of monocytes and macrophages in
vacPSG1 mice by demonstrating a bias towards arginine metabolism in LPS challenged
monocytes and macrophages as well as increased levels of TGF-β1 release from monocytes
and macrophages from vacPSG1 mice. An additive effect on IL-10 release in LPS-stimuated
monocytes and macrophages from vacPSG1 mice, versus controls. It was shown that
macrophages from vacPSG1 mice strongly inhibited naive T-cell proliferation compared to
macrophages from control mice as well as inhibiting their ability to secrete IL-2 and IFN-γ
in response to Concanavalin A.
The Th 2 polarising effect of PSG1 was further investigated by examining the effect of PSG1
on dendritic cells (DCs) which are recognised as highly specialised antigen presenting cells
(APCs) playing a crucial rule in the regulation of innate and adaptive immunity. [157]
demonstrated that PSG1 treated immature DCs showed lower cell surface expression of co-
stimulatory molecules, such as cluster of differentiation (CD)40, CD80, and MHC class II,
compared to control DCs when stimulated with toll-like receptor (TLR)-4 and -9 ligands
and CD40 ligation. In addition, it was found that PSG1 treatment had an additive effect
on CpG- and CD40-stimulated upregulation of programmed death-ligand 1 (PD-L1). The
authors also showed that PSG1-treated DCs showed a stimulus-dependent capability to
modulate the profile of secreted cytokines, thus showing that PSG1 treatment appears to
generate a unique phenotype in DCs. The effect of this Th 2 polarising of DCs on the
adaptive immune response was examined in an elegant in vivo experiment where mice
that had received labelled ovalbumin-specific KJ1-26+ CD4+ T cells were injected intra-
peritoneally with untreated, PSG1 treated, or LPS treated DCs. Five days later, freshly
isolated small mononuclear cells were cultured with ovalbumin peptide for 72 hrs and
cytokine release evaluated by ELISA. IL-4,-5,-10 and -17 release was increased in small
mononuclear cells isolated from mice that were immunised with PSG1 treated DCs. Having
demonstrated the ability of PSGs to modulate the adaptive immune response the authors
then demonstrated that this does not compromise the ability of the immune system to
defend against pathogens using Listeria monocytogenes infection with and without PSG1.
The authors also demonstrated the ability of PSG1 to increase the population of Tr e g cells in
this environment. This paper provides clear evidence of the ability of PSG1 to modulate the
Pregnancy Specific Glycoprotein Function,
Conservation and Receptor Investigation
25 Ronan T. O’Riordan
1. INTRODUCTION 1.2 The CEA family: CEACAMS and PSGs
innate as well as the adaptive immune systems generating a unique immune context, that
is replicated in pregnancy, without compromising anti-microbial defence or tissue repair.
These functions in the context of pregnancy were reviewed in [169].
As well as their immunological functions PSGs are also reported to possess angiogenic
properties. The induction of TGF-β1 and VEGF-A in response to both human and murine
PSGs implies angiogenic functions. It has been further demonstrated that PSG1 induces
tube formation by endothelial cells and thus it has been claimed that PSGs have a role
in placental vascular morphogenesis [158, 170, 155]. Moreover, Psg22 was also shown to
induce edothelial tube formation in the presence or absence of VEGF-A [156].
To date a number of receptors/binding partners have been identified for PSGs. The
tetraspanin, CD9, was shown to bind PSG17 [150]. PSG17 binding was subsequently located
to the EC-2 extracellular loop of CD9, a site important for sperm-egg fusion [151]. The
interaction between CD9 and a truncated PSG17N1 domain protein was shown to be
necessary for PSG17N1 induction of anti-inflammatory cytokines from macrophages[153].
It was also demonstrated for the the first time that human and mouse PSGs could have
different receptors, as absence of CD9 had no effect on PSG1 cytokine induction [153].
[154] further showed that a PSG19N1 protein bound to CD9 and that bacterially produced
PSG17 could not bind to CD9, implying a fundamental role for protein glycosylation in this
interaction. In a critical finding, [171] showed that PSG23N did not bind CD9. In addition, it
was shown that the amino acid sequence of PSG17 required for CD9 binding is located at the
region of highest divergence between murine PSGs. Furthermore it was shown that murine
PSGs bound to cell surface proteoglycans. Importantly, this demonstrated that murine PSGs
could have evolved different receptors potentially mediating novel divergent functions. It
further showed that at least one PSG could bind more than one molecule at the cell surface.
Glycans, oligo and polysaccharides are found almost everywhere in the body and possess a
structural diversity and regulatory capacity beyond that of any other bio-molecule [172].
Because they play a role in cellular interactions they are believed to have evolved these
diverse properties in response to evolutionary conflict [172]. Interestingly, a theory called
The Glyco-Evasion Hypothesis has been proposed to explain how microbial products can
manipulate host glycosylation to the benefit of the pathogen, which could represent a
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selective force for rapid evolution of cell surface glycans [173]. Proteoglycans consist of a
protein core and covalently attached glcosaminoglycan side chains [174].
The binding of PSGs to cell surface proteoglycans was first demonstrated for PSG1 when
glycosaminoglycan side chains were found to be necessary for PSG1-induced endothelial
tubulogenesis [170]. It was also demonstrated that transfection with syndecans1-4 or
glypican-1 rescued PSG1 binding to cells lacking heparan and chondroitin sulphate.
This binding to cell surface proteoglycans was subsequently demonstrated for PSG17N1,
PSG23N1A and PSG22N1A [171, 156]. Importantly, proteoglycans often act as co-
receptors or scaffold proteins for organising clustering of receptors at the cell surface with
roles in adhesion, cell migration, morphogenesis and differentiation[175]. Cell surface
proteoglycans could also act like chaperones for PSG mediating cell membrane binding and
bio-availability, much as has been described for other ligand interactions with HSPGs, such
as VEGF [176]. Notably, syndecans and glypicans are known to interact with, organise and
regulate integrin function [177, 178]. Integrins have been hypothesized to be targets of PSG
function for more than a decade [179].
More recently it was demonstrated that PSGs could bind platelet integrin αIIbβ3 mediating
a novel anti-platelet function, abrogating the interaction between platelets and fibrinogen
[180]. This interaction was not dependent of the KGD tri-peptide that PSG1 shares with
snake venom disintegrin barbourin. Furthermore, it was demonstrated to be mediated
by multiple domains of the protein and to occur with PSG9 and PSG23, indicating a
conserved function. Shanley et al. hypothesised that PSGs evolved to counteract high
levels of fibrinogen (>2 mg/ml) and prevent thrombosis at the placental surface and in
the maternal circulation during pregnancy in haemachorial placental mammals [180]. It
has been further argued this could represent an alternative explanation for the high levels
of PSG in the maternal serum during pregnancy, as opposed to the Maternal-fetal-Conflict
theory [39, 59, 180].
The evidence presented here of both cell surface proteoglycan that interact with and
regulate integrins, and a β3 integrin both binding human and mouse PSGs provides
justification for investigating whether other integrins with roles in immune function,
reproduction and angiogenesis could represent novel binding partners for PSGs. Moreover,
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while the KGD tri-peptide of PSG1 was ruled out as mediator of the PSG1-platelet integrin
αIIbβ3 interaction, it does not preclude the investigation of other K/RGD recognising
integrins such as αVβ3, αMβ2 and α5β1 which are expressed on target cell types such as
endothelium and leukocytes. Thus, the final section of this introduction shall cover the
biological actions and physiological functions of integrins with a goal of elucidating their
function in light of increasing evidence correlating their expression and functions with
those of PSGs.
1.3 Integrins
The ability of cells to interact with each other, the extracellular matrix and the endothelial
surfaces is mediated by membrane proteins called adhesion molecules. These are
composed of selectins, cadherins, mucins, the Ig superfamily and finally the integrins.
Integrins are heterodimeric cell adhesion molecules that affect a number of cellular
functions [181]. They are known to have roles in normal development, metastisis,
angiogenesis and immune function as well as serving as binding partners for pathogens
such as H.pylori and Kaposi’s sarcoma-associated herpes virus [182, 183, 184, 185, 186]. The
24 known integrin heterodimers are generated by the association of 18 α and 8 β subunits
which have so far have been identified in mammals [181]. The expression of integrins, while
wide, is tissue specific, reflecting the specificity of the heterodimers for particular subsets of
extracellular matrix proteins and cell surface ligands. This is important for normal tissue
function and homeostasis. Ligand/integrin interactions activates intercellular signalling
that, depending on the cell type, can be pro-survival, pro-proliferation, pro-migratory and
pro-differentiation. Conversely, detatchment of an integrin from its cognate ligand can
induce pro-apoptotic signals [187]. Integrin signals occur in two directions, both from
the cytoplasm out, ’inside-out’ and vice-versa ’outside-in’. One example is the platelet
integrinαIIbβ3 which is seen to undergo a confirmational change to an active ’open’ state for
fibrinogen binding upon stimulation of platelets with agonists such as thrombin receptor
activating peptide (TRAP) and adenosine diphosphate[188, 189]. ’Outside-in’ signals are
generally a result of binding a specific ligand and generate signals instructing the cell
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about the external environment, directing cellular response to the same [190]. Moreover,
integrins are regulated by extracellular factors such as lipid and/or divalent cation presence
[191]. Dicalent cations such as Ca2+, Mg2+ and Mn2+ are essential for integrin binding and
different cations can differentially affect integrin binding [192].
Integrins are not enzymatic molecules, however they have the ability to recruit a wide
array of intercellular signalling molecules and modulatory enzymes at sites of adhesion,
generating what has been referred to as the adhesome [193]. Integrin adhesions, while
stable, are dynamic structures and their composition can rapidly change altering adhesive
capacity and internal cell signalling [194]. The molecular mechanisms underlying the
crosstalk between the microenvironment and the adhesome are poorly understood [194].
interestingly, compelling evidence that β2 and β3 integrin subunits in various leukocyte
cell types utilise the Immunoreceptor-Tyrosine based Activation Motif (ITAM) adaptors has
recently been generated [195].
1.3.1 Integrins in Immunology and Haemostasis
A fundamental function of leukocytes is their ability to home to an inflammatory site
through attachment to endothelium, extravasation and migration along a chemokine
gradient to the site of inflammation where they carry out their immune functions[196]. The
process of leukocyte recruitment is recognised as an intrinstic part of the immune response
and drugs that target mediators of this represent potential therapeutic compounds. Snake
venom disintegrins have been examined extensively in their ability to modulate leukocyte
activity as reviewed by [197]. RGD disintegrins, Echistatin, Flavoridin and Kirstrin, have
been shown to bind to and modulate T-cell function [198]. Moreover, another disintegrin,
Jararhagin-C was demonstrated to increase rolling of leukocytes in vivo in a mouse model
[199].
Circulating leukocytes generally keep their integrins in an inactive or ’bent’ conformation
which represents a low affinity state for their cognate ligands [190]. Chemokine or cytokine
signals activate inside-out signalling on leukocytes leading to rapid activation of leukocyte
integrins to a high affinity state. There are currently believed to be five steps involved in
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leukocyte recruitment from the vasculature: capturing and rolling, adhesion, postadhesion
strengthening, crawling and transmigration and these are reviewed in [184]. Breifly,
endothelial luminal selectins mediate the capturing of leukocytes from the circulating
blood. This initial interaction causes activation of leukocyte integrins through inside out
signalling, thereby slowing the rolling of the attached leukocyte [200, 201]. Integrins roles
in this are less well studied. In vitro studies suggest integrin α4β1 as β2 integrin blockade
has no effect on monocyte rolling on IL-4 activated HUVEC cells [202]. Integrin α4β1
also appears to be important to lymphocyte rolling [203]. The physiological relevance of
rolling to leukocyte function remains unclear. Adhesion and post adhesion strengthening
in lymphocytes appears to be mediated by integrins α4β1 and αLβ2 whereas in monocytes
it is α4β1 and broadly β2 integrin mediated. Inside out signalling activates these integrins to
bind substrates such as ICAM-1 and VCAM-1 [204]. Intravascular crawling is when attached
monocytes start to migrate to points of cell junctions on the endothelium. These monocytes
have been labelled as ’patrolling’ [205]. αLβ2 blockade decreased monocyte crawling in
vivo however it has been suggested that the crawling of monocytes is dependant on the
cell surface molecule expression with a more αMβ2 dependent crawling found on TNF-α
stimulated endothelial cells [205, 206]. Recently endoglin, an RGD containing endothelial
protein, was shown to be important in integrin α5β1 mediated adhesion and extravastion of
leukocytes [207].
The importance of integrins to this process is evidenced in the symptoms of patients
with Leukocyte Adhesion Deficiency (LAD) disorders. Patients suffering from LAD-I have
mutations in β2-integrin that cause errors in leukocyte/endothelial interactions. Patients
with this type of disorder suffer from recurrent infections due to their compromised
immune response [208, 209]. Patients with LAD-III suffer an additional complication of
bleeding disorders as well as recurrent infections. The reason for this is that these patients
have mutations in an intercellular activator common to both β2 and β3 integrins, kindlin-3.
Platelets from these patients have dramatically lower activation levels [208, 209]. As well as
talin and kindlin, paxillin phosphorylation is known to regulate LFA-1 or integrin β2 activity
and lymphocyte migration [210].
Integrins are known to interact with and regulate latent TGF-β1 [211, 212]. In addition,
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knockout mice for integrins αVβ6 and αVβ8 show similar deformities to TGF-β1 null mice
confirming the functional role of these integrins in TGF-β1 regulation [213]. Furthermore,
this interaction between TGF-β1 and integrins is believed to contribute to tumour growth
and metastasis [214]. αV containing integrins appear to share the ability to activate latent
TGF-β1 [215, 216].
1.3.2 Integrins in Reproduction and Placentation
Integrins have widely acknowledged roles in fertilisation, implantation and placentation.
Given that physiological processes such as cell-cell contact, invasion and adhesion are
critical to normal biology in these processes, this is not surprising. Fertilization is a complex
process that involves the fusion of the gametes of two individuals. Sperm-egg interaction
has multiple players such as ADAMs, CRISPs, SLLP1, SAMP14, SAMP32; immunoglobulins
such as Izumo; integrins; GPI-APs; and tetraspanins [217, 218]. Only Izumo and the
tetraspanin CD9 have been shown to be essential for fertilization [219, 220, 221, 222]. While
multiple integrins have been demonstrated on the murine oocyte surface, knock out mice
for these integrins are fertile leading to the conclusion that "none of the integrins known
to be present on the mouse egg or to be ADAM receptors are essential for sperm-egg
binding and fusion" [223]. However data exists demonstrating a contribution to fertilisation
by sperm and oocyte integrins, including β1, α9 and α6β1 [224, 225, 226]. It has been
demonstrated that RGD tri-peptides can inhibit fertilisation in IVF assays [227]. In addition,
FEE tri-peptides which are recognised by integrin α6β1 potentiate the affect of RGD tri-
peptides [228]. This has led to the hypothesis that there is a cooperation between RGD-
sensitive and RGD-insensitive integrins during human fertilization [229]. Furthermore,
integrin αVβ3 is present in both human gametes where it is believed to play an important
role in fusion events between the two via its ligand vitronectin [230]. This role of spermαVβ3
has also recently been outlined in the mouse [231]. Moreover, it is seen that post fertilisation
entry into normal cell cycle appears to require integrin signalling and phosphorylation of
Focal Adhesion Kinase (FAK) [232].
After fertilisation the embryo develops into a blastocyst which once hatched attaches
to and invades the endometrial surface in a process that has parallels with leukocyte
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extravasation [233]. Cross talk between the endometrium and the blastocyst established
prior to implantation mediates the activity of cell surface receptors, including integrins
[234]. The uterine epithelium expresses selectins and mucins as well as αV integrins as
reviewed in [235]. Blocking antibodies against integrins αVβ3 and α4β1 impair implantation
in the mouse [236, 237]. Conversly, administration of calcitonin increases implantation
through up-regulation of integrin β3 expression on endometrial epithelium [238]. Several
RGD-containing ligands of integrins have been implicated in the implantation process
including osteopontin, fibronectin and thrombospondin [239, 240, 241].
During placental development, trophoblasts require integrins to carry out their normal
barrier and migratory functions. Integrin α6β4 is expressed at the basal surface of both
CTB and STB and is important for barrier functions of the trophoblast [242]. However,
during placental development, and the acquisition of the more invasive phenotype by the
trophoblast lineages, there is a shift to an altered integrin expression pattern compared to
that of the CTB and STB which is characterised by increased expression of integrins α5β1,
α4β1, α6β1 and αVβ3 and decreased integrin α6β4 as reviewed in [51]. The importance of
the β3 integrins to the peri-implantation process as has been demonstrated in the mouse
where it was shown that a switch to integrins αVβ3 and αIIbβ3 from α5β1 occurs during
the invasion of the blastocyst after attachment [243]. This important adhesive role in early
pregnancy for the integrinαIIbβ3 has been demonstrated in tropholbasts isolated from early
human pregnancy also [244]. Together these findings illustrate an important regulatory role
for the platelet integrin αIIbβ3 as part of the orchestrated changes in trophoblast integrin
expression patterns during trophblast differentiation.
Interestingly, the activity of other adhesion molecules and hormones can modify integrin
activity. It was recently shown that MUC-1 is over expressed in patients suffering from
preeclampsia and that forced over expression of this molecule in HTR8/SVneo EVT cells
inhibited invasion and β1 integrin activity [245]. In addition, estradiol was recently shown
to modify integrin expression in baboon pregnancy where artificially raised estradiol levels
negatively impacted on EVT invasion and maternal spiral artery remodelling with integrin
α1β1 and integrin α5β1 expression reduced 2-fold and by 40% respectively [246]. These
accumulated findings confirm the importance of the pattern of orchestrated changes to
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integrin expression, but also demonstrated that maternal signals could play important
roles in the correct execution of these expression changes. Furthermore, it has been
found that atypical expression of integrins is associated with diseases of pregnancy such
as preeclampsia and ectopic pregnancy [247, 248].
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Chapter 2
Materials and Methods
2.1 Molecular cloning
All blunt ligations were performed on end-converted gel extracted PCR fragments into
PSTBlue1 and transformed into NovaBlue Singles ultra-competent E. Coli (Novagen).
Insert-positive colonies were selected by growth on 100 µg/ml ampicillin plates with
isopropyl β-D-1-thiogalactopyranoside (IPTG) and X-gal to allow for white/blue colony
screening. Positive clones were grown overnight shaking examined for insert by
quickscreen or isolation of DNA and diagnostic restriction enzyme digest. Insert was
ligated into vector cut with the same restriction enzymes at room temperature for
two hours with T4 DNA ligase (New England Biolabs). Ligations were transformed
into NEB Turbo ultra-competent E.coli cells (New England Biolabs) and grown on 100
µg/ml ampicillin Luria-Bertani (LB) agar plates. Clones were grown overnight in LB
broth with 100 µg/ml ampicillin shaking at 250 rpm at 37◦C. Bacterial cells were
centrifuged at 2500 rpm for 5 min, plasmid DNA isolated using QIAprep spin mini-
prep kit (QIAGEN, UK) and sent for sequencing (GATC Biotech, Germany) with the
following primers: GATC-pTT3up-611629 5’-CTCTCAAAAGCGGGCATTA-3’ and GATC-
pTT3Reversesequencingprimer-612690 5’-GAGGGATCTCGACCAAATGA-3’.
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2.2 Generation of pTT3hCEACAM1∆430-465 construct
An expression construct encoding a c-terminal V5 6xHis tagged truncated form of the
human CEACAM1 gene minus the c-terminal membrane targeting component designated
pTT3CEACAM1∆430-465, was generated by polymerase chain reaction (PCR) amplifying
the CEACAM1∆430-465 sequence incorporating 5’ EcoRI and 3’ HindIII restriction sights
from pcDNA3.1
hCC1-4S which encodes the human CEACAM1-4S isoform (Genbank accession number
DQ975209) (a kind gift from Dr. Bernhard Singer, Institute for Anatomy, Clinical University
of Essen) using the following primers: hCC1For 5’aGAATTCaccatggggcacctctcagcc 3’ and
hCC1Rev430-465del 5’aAACCTTggccccaggtgagaggccattttat3’. The PCR amplified band was
blunt cloned as described in Section 2.1. The insert was digested out of pSTBlue1 with EcoRI
and HindIII and ligated into a digested, modified pTT3 construct that had been mutated to
incorporate EcoRI and HindIII RE sites before the pBluescript polylinker and V5 6xHis tag
(pTT3-B). pTT3 is a modified version of the pTT vector with an extended multiple cloning
[249] See Appendix Fig.7.1 (A) and (B) for vector maps of pTT3 and pTT3-B PSG1.
2.3 Mutation of pTT3 PSG constructs by PCR
pTT3PSG1, pTT3PSG1∆N, pTT3PSG1∆A1A2, pTT3PSG1∆B2cterm, pTT3PSG1 KGD→AAA,
pTT3PSG1N, pTT3PSG1N KGD→AAA, pTT3PSG9 and pTT3PSG23 were generated as
previously described [180]. PCR mutagenesis of pTT3PSG1 and pTT3PSG9 constructs
for this study was performed with Phusion II Taq Polymerase (Finnzymes) as outlined in
Table 2.1. This was followed by ligation of PCR product with T4 DNA ligase (New England
Biolabs) and transformation into NEB Turbo ultra-competent E. coli (New England Biolabs).
pTT3PSG4 was generated by Mrs Melanie S. Ball, by amplifying the PSG4 coding-domain
sequence (CDS) from a commercially available clone (Source Bioscience, UK) incorporating
5’ EcoRI and 3’ HindIII restriction sites. This was blunt cloned into PSTBlue1 and subcloned
into pTT3-B using EcoRI and HindIII restriction enzymes as described in section 2.1.
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Table 2.1: Templates, primers and conditions for pTT3 PSG mutagenesis
Template Primers Conditions Construct
pTT3PSG1∆N
F 5’ aagcttaggcctggtaagcctatcccta 3’
R 5’ aatcagggtgactgggtcactgc 3’
98◦C 3 min, [98◦C 10 sec,
65◦C 30 sec, 72◦C 3 min] x
25, 72◦C 10 min
pTT3PSG1A1
pTT3PSG1∆B2
F 5’ cccaagccctacatcaccatc 3’
R 5’ ggcagtggtgggcaggtt 3’
98◦C 3 min, [98◦C 10 sec,
65◦C 30 sec, 72◦C 3 min] x
25, 72◦C 10 min
pTT3PSG1A2
pTT3PSG1
∆A1A2
F 5’ tatggtccagacctccccaga 3’
R 5’ ggcagtggtgggcaggtt 3’
98◦C 3 min, [98◦C 10 sec,
65◦C 30 sec, 72◦C 3 min] x
25, 72◦C 10 min
pTT3PSG1B2
pTT3PSG1∆N
F 5’ cctggtaagcctatccctaaccctct 3’
R 5’ cctaacttgaggacattcagg 3’
98◦C 3 min, [98◦C 10 sec,
65◦C 30 sec, 72◦C 3 min] x
25, 72◦C 10 min
pTT3PSG1A1A2
pTT3PSG1
F 5’ gatcttaccggctacatctggtacaaag 3’
R 5’ ctggggcaaattgtcgacaagtagaaga 3’
98◦C 3 min, [98◦C 10 sec,
65◦C 30 sec, 72◦C 3 min] x
25, 72◦C 10 min
pTT3PSG1
N61D
pTT3PSG1N
F 5’ gatcttaccggctacatctggtacaaag 3’
R 5’ ctggggcaaattgtggacaagtagaaga 3’
98◦C 3 min, [98◦C 10 sec,
65◦C 30 sec, 72◦C 3 min] x
25, 72◦C 10 min
pTT3PSG1N
N61D
pTT3PSG1N
F 5’ gcatattccgatgcatccctgct 3’
R 5’ tgtttctcgtccactatatgcag 3’
98◦C 3 min, [98◦C 10 sec,
65◦C 30 sec, 72◦C 3 min] x
25, 72◦C 10 min
pTT3PSG1N
N104D
pTT3PSG1
N111D
F 5’ aagcttaggcctggtaagcctatcccta 3’
R 5’ caggtgtaaggtgaaggtgaaacgtc 3’
98◦C 3 min, [98◦C 10 sec,
65◦C 30 sec, 72◦C 3 min] x
25, 72◦C 10 min
pTT3PSG1N
N111D
pTT3PSG1N
N111D
F 5’ gatcttaccggctacatctggtacaaag 3’
R 5’ ctggggcaaattgtggacaagtagaaga 3’
98◦C 3 min, [98◦C 10 sec,
65◦C 30 sec, 72◦C 3 min] x
25, 72◦C 10 min
pTT3PSG1N
N61, 111D
pTT3PSG1N
N111D
F 5’ gcatattccgatgcatccctgct 3’
R 5’ tgtttctcgtccactatatgcag 3’
98◦C 3 min, [98◦C 10 sec,
65◦C 30 sec, 72◦C 3 min] x
25, 72◦C 10 min
pTT3PSG1N
N104, 111D
pTT3PSG1N
N104, 111D
F 5’ gatcttaccggctacatctggtacaaag 3’
R 5’ ctggggcaaattgtggacaagtagaaga 3’
98◦C 3 min, [98◦C 10 sec,
65◦C 30 sec, 72◦C 3 min] x
25, 72◦C 10 min
pTT3PSG1N
NNN→DDD
2.4 Generation of pTT3CEACAM49 construct
The pTT3CEACAM49 construct was generated by PCR amplifying the CEACAM49 CDS from
pRcCMV-ecaCEACAM49 (a kind gift from Dr. Robert Kammerer, Institute of Immunology,
Friedrich-Loeffler-Institute, Teubingen, Germany) incorporating 5’ EcoRi and 3’ HindIII
restriction sites by Mrs Melanie Ball using the following primers; ecaCEACAM49For
5’gGAATTCaccatgcaatcaccctca3’ and ecaCEACAM49Rev 5’cAAGCTtggctctgtaactgggg3’. The
PCR amplified band was blunt cloned into PSTBlue1 and sub-cloned into pTT3-B using
EcoRI and HindIII restriction enzymes as described in Section 2.1.
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2.5 Generation of Recombinant Proteins
2.5.1 Endotoxin Free plasmid DNA Preperation
E. coli containing the PSG construct to be expressed were grown in 300 ml of 25 g/L Luria
Broth (Sigma) with 100 µg/ml ampicillin overnight, shaking at 250 rpm at 37◦C. Cells were
isolated by centrifugation at 6,000 rpm in a Beckman Avanti™ J-25 centrifuge. Endotoxin
free plasmid DNA was isolated using the Nucleobond Xtra Maxi EF pasmid DNA extraction
kit (Machery-Nagel, Germany) as per the manufacturer’s instructions. DNA reconstituted
in endotoxin free water was quantified by measuring absorbance at λ280 and aliquoted in
endotoxin free eppendorf tubes and stored frozen at -20◦C.
2.5.2 Transient transfection of Freestyle™ 293 cells
250µg of plasmid DNA and 250 µl of Freestyle™ MAX Reagent (Invitrogen Life
Technologies) were each diluted independently in 5 ml of OptiPRO™ serum free media
(Gibco® Life Technologies) and subsequently mixed and incubated at room temperature for
12 minutes. This 10 ml transfection mix was added slowly to 250 ml of antibiotic antimycotic
solution (AAS)-free Freestyle™293 cells at 1.0 x 106 cells/ml. The transfected cells were
incubated for a further 72 hrs. The PSG containing media was separated from cells and
particulate matter by centrifugation at 1,500 rpm and stored at -80◦C.
2.5.3 Nickel Agarose Affinity Chromatography
250 ml PSG media was thawed and Imidazole added to a 10 mM final concentration. 2.5
ml of HisPur Ni-NTA resin in 20% ethanol (Fisher-Thermo Scientific) was washed in wash
buffer (500 mM NaCl, 20 mM NaH2PO4, pH 6.0) and added to the imidazole supplemented
PSGmedia. This was incubated rotating at 8 rpm overnight at 4◦C. All subsequent steps
were carried out at 4◦C. The beads were settled out in a disposable polypropylene column
and washed with 60 ml of wash buffer. The last 4 x 1.5 ml of wash was collected to check
for absence of contaminating protein. PSG was eluted by increasing concentrations of
imidazole (50 - 500 mM) in wash buffer and collected in 1.5 ml fractions (4 x 50 mM, 5 x 200
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mM, 3 x 300 mM, 3 x 500 mM). 22.5 µl of fractions were separated by SDS PAGE and stained
with Gelcode® Blue to examine purity and elution pattern of PSG. Gels were de-stained
further for 1 hr in distilled water and scanned on the Odyssey infrared imaging system (Li-
Cor Biosciences, UK) using protein gel system settings at 700 nm.
2.5.4 Concentration
Positive fractions free from contaminating protein were pooled and added to a washed
Centrifugal Filter Unit with a 30 KDa molecular weight cut-off (MWCO) (Millipore, Ireland).
This was centrifuged at 3,800 rpm at 4◦C until the PSG solution was concentrated greater
than 100-fold.
2.5.5 Dialysis
The concentrated PSG solution was injected into a pre-hydrated Slide-A-Lyzer® Dialysis
cassette (Millipore) with a 10 KDa cut-off and 0.5 - 3 ml capacity. The solution was dialyzed
in 500 times its own volume in sterile-A PBS in an LPS-free container for 2 x 3 hrs and
overnight at 4◦C.
2.5.6 Quantification
The PSG protein, now in PBS, was removed from the cassette and quantified by measuring
the absorbance of 5 µl of the protein in 95 µl water at λ280. This figure was then divided
by a protein specific figure for predicted absorbance at λ280 at 0.1% (=1g/L), determined
by entering the protein sequence minus the 35 amino acid leader sequence into the Expasy
ProtParam online tool. The predicted absorbance at at λ280 at 0.1% (Abs 0.1%) for each
protein is indicated in Table 2.2. Protein purity was assessed by SDS-PAGE and Gelcode®
Blue staining as in section 2.5.3.
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Table 2.2: Protein Abs @ 0.1% from Expasy ProtParam tool
Protein Abs @ 0.1% Protein Abs @ 0.1%
CEACAM1∆TM 1.236 PSG1 1.608
PSG1∆N 1.629 PSG1A1A2 1.421
PSG1
KGD→AAA 1.611
PSG1
N61D/N111D
1.608
PSG1N 1.240
PSG1N
KGD→AAA 1.247
PSG1N
N61D/N111D
1.240 PSG1A1 1.199
PSG1A2 1.374 PSG4 1.642
PSG9 1.518 CEACAM49 1.019
2.5.7 Size Exclusion Chromatography
1-4 mg of purified recombinant protein was applied to a HiLoad 16/60 Superdex S200
prep grade column in a 1 ml volume with a flow rate of 1 ml/min using the Akta explorer
system in PBS. Determination of 1 ml fractions to pool was based on chromatogram
peaks and is indicated on graphs. Resultant protein solution was concentrated and
visualised as previously described to confirm removal of non-specific contaminating
bands. The presence/absence of contaminating TGF-β1 was determined by enzyme-linked
immunosorbent assay (ELISA).
2.6 Cell Culture
THP-1 cells were purchased live from the European Collection of Cell Cultures (ECACC).
Cells were maintained between 0.3 - 1.0 x 106 cells/ml in RPMI-1640 supplemented with
10 % fetal bovine serum (FBS), 100 U/ml penicillin-streptomycin antiobiotic and 20 mM L-
glutamine. HUVEC-2 endothelial cells were purchased frozen from BD Biosciences. Cells
were resuscitated and maintained in Enhanced Growth Media (EGM-2) (Lonza). Cells were
seeded at a 2,500 cells/cm2 through each passage and not allowed grow to confluency. THP-
1 cells and HUVEC-2 cells were grown at 37◦C in a 5 % CO2 atmosphere. Freestyle™ 293
cells (Invitrogen-Life Technologies) were maintained in Freestyle™ expression medium
(Gibco®-Life Technologies) supplemented with AAS(Gibco®-Life Technologies) between
0.3 - 1.0 x 106 cells/ml shaking at 100 rpm, at 37◦C in an 8 % CO2 atmosphere. For
transfection Freestyle™ 293 cells were twice passaged free of AAS and grown to 1.0 x
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106 cells/ml. Mock and integrin αIIbβ3 dual over-expressing CHO-K1 cells were grown
in DMEM-F12 media supplemented with 10 % FBS, 100 U/ml penicillin-streptomycin
antiobiotic, 20 mM L-glutamine, G418 and Zeocin. RAW 264.7 and integrin αVβ3 dual
over-expressing CHO-K1 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10 % FBS, 100 U/ml penicillin-streptomycin antiobiotic and 20 mM
L-glutamine. Integrin β3 sub-unit over-expressing CHO-K1 cells were grown in DMEM
supplemented with 10 % FBS, 100 U/ml penicillin-streptomycin antiobiotic, 20 mM L-
glutamine and G418.
2.7 Treatment of cells with PSG
THP-1 cells were treated at 3 x 105 cells/ml in 1 ml volumes in 24 well plate. HUVEC-2
endothelial cells were treated in 1 ml in 24 well plate with 3 x 105 cells/well. All treatments
were carried out in the same volume in phosphate buffered saline (PBS). PBS alone was
included as a vehicle control. Where indicated, human IgG and human CEACAM1-Fc along
with CEACAM1∆TM were used as non-specific protein controls. Cells were treated for the
indicated times, at the indicated concentrations and media or nucleic acids were harvested
for analysis.
2.8 Western Immunoblotting
2.8.1 Preperation of Whole Cell Lysates
Cells were lysed in NP-40 lysis buffer (20mM Tris, pH 8.0, 50mM NaCl, 50mM NaF, 1% NP40).
Lysis buffers were supplemented with inhibitors (1 mM Sodium Orthovanadate, 2 µg/ml
Aprotinin, 1 mM pefabloc, and 1 mM pepstatin-A). All samples were lysed on ice for 20mins,
centrifuged at 14,000rpm at 4◦C for 20 mins and supernatents removed to fresh tubes and
maintained at -80◦C. Large lysates were aliquoted to avoid multiple freeze/thaw cycles.
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2.8.2 Protein Concentration Determination
The bicinchonic acid (BCA) Protein Assay Kit (Novagen, CA, USA) was used to determine
protein concentration of all samples. Serial dilutions of bovine serum albumin (BSA)
were used to generate a standard curve, from which sample protein concentrations
were estimated. Absorbance values at 562 nm were obtained using a SpectraMAX340
spectrophotometer and SOFTMax Pro software (Molecular Devices Corp.).
2.8.3 SDS PAGE and Immunoblotting
Proteins were resolved on 10 or 12% acrylamide gels (1.5 M Tris (pH 8.8), 10% SDS, 10%
ammonium persulfate, dH2O and tetramethylethylenediamine (TEMED)), depending on
the molecular weight of the protein of interest. Equal amounts of proteins were loaded
into a 5% acrylamide stacking gel (1M Tris (pH6.8), 10% SDS, dH2O and TEMED) using
Laemmli buffer (62.5mM Tris-HCL (pH 6.8), 2% w/v SDS, 15% v/v glycerol, 3% v/v β-
mercaptoethanol). Proteins were denatured by boiling at 100◦C for 5 mins before being
resolved at 120-150V using standard electrophoresis buffer (25 mM Tris, 192 mM glycine,
0.1% SDS). Proteins were then transferred electrophoretically to 0.2 µm pore nitrocellulose
membranes (Millipore, ) using transfer buffer (48mM Tris, 39mM glycine and 20% ethanol)
at 20 V for 60 mins at room temperature with a semi dry transfer apparatus. Membranes
were incubated with a blocking buffer containing PBS, 0.1% Tween-20 (PBS-T) and either
5% w/v non-fat desiccated milk (Marvel, Chivers Ltd, Dublin, Ireland) or 5% BSA for 1hr
at room temperature on a rocking platform at approximately 35rpm. Immunoblots were
then incubated overnight at 4◦C with primary antibody solutions diluted in 5% non-fat milk
or 5% BSA on a rocking platform. Membranes were washed 3 x 5mins and 2 x 10mins in
PBS-T and incubated for 1hr with Alexa Fluor 680 and 800-coupled anti-mouse secondary
antibodies (LI-COR Biosceiences, UK) diluted in PBS-T (1:10,000) containing 5% non-fat
milk for 1hr at room temperature on a rocking platform. Immunoblots were then washed in
PBS-T as above. Immunoreactive proteins were visualized on the Odyssey Infrared imaging
system using manufacturers settings (LI-COR Biosciences, UK). An exception was rabbit
anti IκBα primary antibody which was detected with a horse radish peroxidase conjugated
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secondary antibody (). Following washing, as above, the bands were detected with
enhanced chemiluminescence substrate () with exposure to photographic film (Thermo
Scientific, Rockford, IL, USA) which was developed using an automated CP100 developer
(AGFA, Gevaert, NV, Germany).
2.9 Fibrinogen Binding Assay
2.9.1 Preparation of Human Platelets
Platelets were obtained from healthy volunteers that were free of medication under Royal
College of Surgeons in Ireland (RCSI) Ethical Review Protocol. Platelets were collected into
0.15 vol/vol acid-citrate dextrose (ACD, 75 mM trisodium citrate, 124 mM dextrose and 38
mM citric acid) anticoagulant and washed using a modification of a previously described
method(ref). Briefly, blood was centrifuged at 150 x g for 10 min at room temperature. In
order to avoid any contamination from the buffy coat, 0.5 ml of the platelet-rich suspension
above the buffy coat layer was left behind in the centrifugation tube. platelet rich plasma
(PRP) was then acidified to pH6.5 with acid-citrate-dextrose (ACD) and Prostaglandin E1
(PGE1, 1 mM) was added. The platelets were pelleted by centrifugation at 750 x g for
10 min at room temperature. The supernatant was removed and the platelet pellet was
gently resuspended in JNL buffer (130 mM NaCl, 3 mM KCl, 10 mM trisodium citrate,
9 mM NaHCO3, 6 mM dextrose, 0.9 mM MgCl2, 0.81 mM KH2PO4, 10 mM Tris pH7.4).
Platelet count was adjusted to 3 x 108/ml using a Sysmex XE K-1000 counter (Toa Medical
Electronics Co. Ltd, Kobe, Japan). Platelets were allowed to stand at room temperature
for 45 min to let PGE1 dissipate. Calcium chloride (CaCl2, 1.8 mM) was added to platelets
immediately before use.
2.9.2 Fibrinogen Binding Assay
10 µl of 2.5 mg/ml Oregon Green 488 fibrinogen (OGFg)-conjugate labeled Fibrinogen
(Invitrogen, UK) was added to 20 µl aliquots of washed platelet suspension along with
the indicated concentrations of wildtype PSG1 and CEACAM49 in successive tubes. All
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2.10 Primary Bone Marow-Derived Macrophage
Isolation and Culture
experiments were run in duplicate at least three times. The platelet suspension was
vortexed and allowed to stand at room temperature for 10 min before the addition of 3.4
µM TRAP (Bachem, UK), a dose known to produce a 50% maximal response as measured
by aggregometery in pilot studies. Assay tubes were incubated at room temperature
for a further 10 min. The reaction was stopped by addition of 1 ml ice-cold buffer.
The association of OGFg with platelets was detected using the BD FACSCalibur system.
Data acquisition and analysis were performed with the Cell Quest program. Platelet
populations were gated, and histograms of mean fluorescence were generated for each
sample. Statistical analysis was performed on the geometric scale.
2.10 Primary Bone Marow-Derived Macrophage Isolation and
Culture
6-8 week old CH3/HEN mice were sacrificed by rapid cervical dislocation. Femur and tibial
bones were harvested and cleaned. Marrow was flushed with 5 ml of 10% FBS DMEM with
Pen/Strep and L-glutamine. Cells were centrifuged at 1500 rpm for 7 minutes, supernatant
discarded and resuspended in BMM media (20% DMEM with Pen/Strep, L-glutamine
supplemented with 10 ng/ml murine-colony stimulating factor (M-CSF)). Cells were seeded
and allowed to differentiate over 7 days. Cells were supplemented with fresh media on day
3, washed on day 5 with PBS and fresh media applied. On day 7 cells were washed in PBS
and harvested by incubation with non-enzymatice cell dissociation solution (PBS with 5
mM ethylenediaminetetraacetic acid (EDTA), 4 mg/ml lidocaine, 0.22 µm filtered) for 20
minutes and scraped. Cells were centrifuged for 7 minutes at 1000 rpm and resuspended
in 10% DMEM, counted and seeded at required density. Cells were stained for F4/80 and
scanned on a BD FACSCalibur system to verify macrophage phenotype.
2.11 PSG1 pre-treatment and LPS challenge of BMDM
Cells seeded at 2 X104 cells/well in a 96 well plate overnight were pre-treated with 5 µM
(250 µg/ml) PSG1 for 30 minutes. Cells were subsequently challenged with 10 ng/ml, 100
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2. MATERIALS AND METHODS 2.12 Quantitative Real-time PCR
ng/ml or 1 µg/ml LPS for 6 and 18 hrs. Media was harvested, centrifuged at 5000 rpm to
remove cellular debris and stored at -20◦C. Supernatants were applied to IL-6, IL-10 and
TNF-α ELISAs (e-biosciences, Germany) as per the manufacturers instructions.
2.12 Quantitative Real-time PCR
Total ribonucleic acid (RNA) was isolated using TRI-Reagent®(Sigma-Aldrich, UK). cDNA
was generated using High Capacity cDNA Reverse Transcription kit (Applied Biosciences)
with 1µg of RNA per 20µl reaction. quantitative real-time reverse transcriptase-polymerase
chain reaction (qRT-PCR) was carried out using the Roche Universal Probe Library and the
Lightcycler®480 Probes Master on the LC480 real time PCR system with 10 µl PCR reactions
in triplicate composed of 7.5 µl LC480 PCR mix and 2.5 µl of 1:2 dilution of cDNA. Primer
and fluorescent probe pairs used are shown in Table 2.3.
Table 2.3: Primer-Probe pairs for Quantitative Real-time PCR
Gene Primers Probe
Human
ACTB
L 5’ attggcaatgagcggttc 3’
R 5’ ggatgccagaggactccat 3’
11
TNF
L 5’ cagcctcttctccttcctga 3’
R 5’ gccagagggctgattagaga 3’
29
IL6
L 5’ agctatgaactccttctccacaa 3’
R 5’ ggtactggggcagggagg 3’
68
IL10
L 5’ tgccttcagcagagtgaaga 3’
R 5’ gcaacccaggtaacccttaaa 3’
67
TGFB1
L 5’ gagcccaagggctaccat 3’
R 5’ gggttatgctggttgtacagg 3’
29
CCL3
L 5’ tgcccttgctgttcttctct 3’
R 5’ gtggaatcttccggctgtag 3’
40
Mouse
Actb
L 5’ tgacaggatgcagaaggaga 3’
R 5’ cgctcaggaggagcaatg 3’
106
Rpl9
L 5’ caggctgacgagtgaggag 3’
R 5’ gcccaaattgttcatgtggt 3’
72
Cxcl2
L 5’ aaaatcatccaaaagatactgaacaa 3’
R 5’ ctttggttcttccgttgcgg 3’
26
Ccl2
L 5’ gatcatcttgctggtgaatgagt 3’
R 5’ catccacgtgttggctca 3’
62
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2.13 In-vitro Integrin Binding Assay
To bind integrinsαIIbβ3 andαVβ3 to Protein G agarose beads, 2µg of purified integrinαIIbβ3
from human platelets (Calbiochem, UK) and 2 µg of purified integrin αVβ3 from human
placenta (Millipore, US) were added to a tube containing 700 µl of immunoprecipitation
(IP) buffer (100 mM NaCl, 0.1% NP-40, 1 mM CaCl2, 20 mM TrisHCl pH 7.4 plus the tyrosine
phosphatase inhibitor Na3VO4 (1 mM) and the protease inhibitors PMSF (1 mM), pepstatin
(1 µM) and aprotinin (1.5 µg/ml).). 3 µg of the anti- integrin αIIbβ3 monoclonal antibody
(mAb) (clone SZ22, Beckman Coulter, Ireland) and 5 µl of anti integrin αV mAb (clone
LM142, Millipore, Ireland) were added to the respective tubes overnight at 4◦C with gentle
rocking. The next day Immune complexes were obtained by adding 40 µl of Protein G
agarose beads (Thermo-Fisher, UK) for 3 h at 4◦C followed by three washes with ice-cold
IP buffer. For the in vitro binding assay, the last wash was removed from each of the
samples and contols and the Protein G agarose beads were incubated with 2 µg of PSG1.
All samples were incubated on a rotator for 1 h at room temperature. The beads were
recovered by centrifugation at 3,000 rpm for 3 min followed by extensive washing to remove
unbound PSG1. Protein was removed from the beads by boiling for 5 min in 20 µl of 2X SDS
PAGE sample buffer before electrophoresis and western immunoblot analysis as previously
described. For immunoblotting all primary and secondary antibodies were diluted in 5%
milk. Mouse anti- integrin αIIbβ3 mAb (clone SZ22, Beckman Coulter, Ireland) was used at
1 in 800 dilution, mouse anti-CD51 (BD Biosciences) was used at 1 in 500 dilution, mouse
anti-PSG mAb11 ascites was used at 1 in 200 dilution.
2.14 Fluorescence Activated Cell Sorting
(Assisted by Ken Martin, Centre for Research in Vascular
Biology, UCC)
Integrin αIIbβ3 dual transfected CHO-K1 cells were enriched for highly expressing
population by Fluorescence Activated Cell Sorting (FACS) using the FACS Aria II system (BD
Biosciences). Briefly, mock and integrin αIIbβ3 dual transfected CHO-K1 cells were non-
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enzymatically detached (0.2% EDTA) and washed in cell sorting buffer (1% FBS, 1 mM EDTA,
25 mM HEPES in PBS). 1 x 106 cells in 100 µl of cell sorting buffer were incubate with 20 µl
of phycoerythrin (PE)-conjugated mouse anti-CD41a (BD Pharmingen) for 30 mins on ice
in the dark. Cells were washed twice in 5 ml of cell sorting buffer, resuspended in 1 ml and
sorted as indicated using a BD FACS Aria-II . Enriched cells were propagated and used in
ligand binding experiments. The protocol for integrin β3 CHO cells and mock controls was
the same but with APC-labelled anti-CD51 (BD biosciences ). FACS on integrin α5β1 cells
and mock controls was performed with anti-α5β1 antibody (Beckman Coulter) and FITC-
labelled secondary antibody (Jackson immunoResearch).
2.15 Fluorescent Labelling of PSG1
1 mg of recombinant PSG1 was labelled with an N-hydroxysuccinimide (NHS) ester-
activated Dylight®-800 or -488 fluorophore (Thermo Scientific), and excess fluorophore
removed, as per the manufacturer’s instructions. Labelled protein was aliquoted and stored
at -20◦C.
2.16 Multi-channel FACScan analysis of fluorescent PSG1 binding
to primary leukocytes
(Assisted by Andreia Ribreiro, ReMedI, NUIG)
Leukocyte samples were obtained using Ficoll-Hypaque separation of whole blood isolated
from healthy volunteers in EDTA-Vacutainers (BD, UK) under NUIG Ethical Review
Protocol. Buffy coat was harvested and washed in FACS buffer (PBS pH 7.4, 3 % BSA, 0.05
% NaN3). Cells were counted on a BD Accuri®C6 flow cytometry system and adjusted to
the same concentration in FACS buffer. Fluorescent PSG1 was added along with mouse
anti-CD14-APC (e-biosciences, Germany) for identification of monocyte sub-population
alone or mouse anti-CD14-APC in conjunction with mouse anti-CD45-PerCP Cy5.5 (e-
biosciences, Germany) for seperation of monocyte and lymphocyte sub-populations.
PSG1488 was added at 50 µg/ml unless stated otherwise for 30 mins at RT in the dark.
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2.17 FACScan analysis of fluorescent PSG1 binding to
cell lines
Treatments were in 100 µl volumes. Blocking antibodies were used at 20 µg/ml and added
as a cotreatment. Post acquisition compensation and analysis was carried out using the
Infinicyt™software package.
2.17 FACScan analysis of fluorescent PSG1 binding to cell lines
THP-1 cells were washed and re-suspended in FACS buffer at a concentration of 1 x 107
cells/ml. Fluorescent PSG1488 was added at 50 µg/ml to 100 µl of cell suspension and
incubated for 1 hr on ice with before washing and fixing at 37◦C for 10 mins in 4%
paraformaldehyde (PFA)-PBS pH 7.4. Cells were washed in PBS and re-suspended in 1 ml of
PBS before being scanned on a BD FACSCalibur system. Data were analysed using the BD
Cell Quest Pro software.
2.18 Fluorescent Ligand Binding Assay
Stable empty vector transfected (Mock) and integrin αIIbβ3 over-expressing cells were
seeded in quadruplicate in 96-well plates in selective media at 60,000 cells per well and
allowed to adhere overnight. The next day the wells were washed in PBS and 100 µl of
selective media with 50 µg/ml of PSG1800 was applied to the cells for 30 mins at 37◦C. Wells
that had been blocked with media overnight were used as controls for background binding
of PSG1800. Media was removed and wells were washed extensively and fixed in fresh 4%
PFA-PBS pH 7.4 for 20 min at room temperature or overnight at 4◦C. The cells were washed
once in PBS and a 1:10,000 dilution of the SYTO®60 red fluorescent nucleic acid stain
(Molecular Probes) in dH2O was applied was applied for 1 hr at room temperature. Wells
were washed three times with dH2O and plate allowed to dry. The plate was scanned on a LI-
COR Odyssey®Infrared Imaging System using the manufacturer’s microplate settings. The
mean fluorescence intensity for each well in the red and green channels was determined
using the supplied software. Data from the green channel were normalized to the red
channel.
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2.19 Indirect Fluorescent Ligand Binding Assay
Mock and over-expressing cells were seeded as previously described in section 2.18. The
next day the wells were washed in PBS and 100 µl of selective media with 50 µg/ml of
PSG1 or a 1 in 4 dilution in culture media of a pool of six third trimester plasma samples
from pregnant women were applied to the cells for 30 mins at 37◦C. The cells were washed
in PBS and fixed in 4% PFA-PBS pH 7.4 overnight at 4◦C. Subsequently 100 µl of mouse
anti-PSG mAb5 hybridoma supernatant was applied to the indicated wells for 1 hr at
room temperature. The wells were washed three times and 75 µl of a 1 in 75 dilution of
goat anti-mouse IRDye680 was applied to the wells for 1 hr at room temperature. The
wells were washed and scanned on a LI-COR Odyssey®Infrared Imaging System using the
manufacturer’s microplate settings. A 1:10,000 dilution of the SYTO®60 red fluorescent
nucleic acid stain (Molecular Probes) in dH2O was applied was applied for 1 hr at room
temperature to the unstained wells to control for cell number. The plate was washed and
scanned again at a lower intensity. The mean fluorescent intensity for the background was
subtracted from the sample mean fluorescent intensity which was subsequently normalised
to the SYTO®60 staining.
2.20 Endothelial-monocytic interaction assay
HUVEC-2 endothelial cells were seeded in a 24 well plate at a density of 2.5 x 105 cells/well
and allowed to adhere before being treated for 12 hr with 10 ng/ml TNF-α. Monocytic THP-
1 cells were subsequently labelled with Cell Tracker™Green CMFDA (Molecular Probes®)
according to the manufacturers instructions. Labelled cells were pre-incubated with
treatments indicated for 30 min before application of 1 x 106 cells/well to the washed
monolayer and allowed to adhere for the indicated times before being washed in PBS and
fixed overnight in 4% PFA-PBS pH 7.4 overnight at 4◦C. Wells were washed gently in PBS,
allowed to dry and imaged on a Leica DMI3000 B microscope attached to a Leica DFC420 C
CCD camera.
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2.21 Bioinformatics
All human
and rodent PSG sequences were taken from publicly accessible genome browsers; National
Centre of Biotechnology Institute (NCBI) (http://www.ncbi.nlm.nih.gov), University College
of Santa Cruz (UCSC) (http://genome.ucsc.edu) and the Ensembl Genome Browser
(http://www.ensembl.org/index.html) as represented in Table 2.4 compiled by (Williams,
J. 2013). Horse, Ape and Baboon sequences were taken from Kammerer and Zimmermann
2010 and supplemented with extra Horse sequence data provided by Robert Kammerer in a
personal communication [58].
2.21.1 Alignments
Sequence alignments were performed using the online ClustalW alignment software
(http://www.ebi.ac.uk/tools/clustalw2/index.html)
2.21.2 Generation of Phylogenetic Trees
Utilising ClustalW aligned PSG N domain CDSs lacking the leader sequence, the MEGA5
Molecular Evolutionary Genetics Analysis software was employed to construct phylogenetic
trees (Neighbour-joined pairwise comparison). The evolutionary history was inferred by
using the maximum likelihood method based on the Tamura-Nei model (citation). The
bootstrap consensus inferred from 1000 replicates is taken to represent the evolutionary
history of the taxa analysed (citation). The percentage of replicate trees in which the taxa
clustered together in the bootstrap test are shown next to the branches. All major branches
yielded values of 95-100%.
2.22 Statistical Analysis
All statistical analyses were carried out using Graph Pad Prism 4 statistical analysis software
package (GraphPad software Inc, La Jolla, CA, USA). Analyses used and sample numbers are
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2. MATERIALS AND METHODS 2.22 Statistical Analysis
indicated under figures. In all figures * = P<0.05, ** = P<0.01 and *** = P<0.001.
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Chapter 3
Mutation of PSG1 and analysis of its
immunomodulatory function
3.1 Introduction
As described earlier, thirteen years of published work has shown PSGs to be
immunomodulatory, and pro-angiogenic hormones that can directly induce various
cytokines from several cell types with roles in pregnancy and placentaion, in a cross-species
reactive manner [147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157]. More recently it was
demonstrated that they possess novel anti-platelet properties, disrupting the interaction
between platelet integrin αIIbβ3 and fibrinogen, a function that it is argued evolved
in answer to the haemostatic complications associated with haemochorial placentation
[180]. Many of the studies listed have investigated functional elements within PSGs
through the expression of truncated constructs and the mutation of residues with proposed
functional importance. Constructs studied for cytokine induction include: PSG6N [149],
PSG17N1 [150, 151, 153, 158, 171], PSG18N1 [148], PSG19N1[154, 171], PSG22N1A [156],
PSG23N1A[158, 171], and PSG23N1 [171]. It must also be noted that two of the recent
papers published on PSG1, make use of a truncated form of the protein lacking the A2
domain [155, 170]. This list shows that most studies on the immune functions of PSGs have
examined truncations of the murine proteins and have almost entirely focused on the IgV-
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type N/N1 domains.
McLellan et al. proposed that a conserved RGD-like tri-peptide in primate N and rodent
N1 domains may be of functional importance [81]. Ha et al. examined this in a mutant
PSG1 construct lacking the A2 domain where the Glycine-Aspartic acid-Aspartic acid
(GDD) on the solvent exposed F-G loop was mutated to Serine-Aspartic acid-Leucine
(SDL), the sequence that is found in this location in CEACAM1 [155, 75]. The authors
concluded these residues were unimportant for PSG1-induced TGF-β1 release. In the
same paper, an asparagine (N) important for the formation of a salt bridge in conjunction
with two conserved glycosylation sites in the PSG1 N-domain were also investigated in
a single mutant and collectively were proposed to ablate PSG1 function. Mutations in
glycosylation site number in proteins are known to affect protein function, as is the case
in occulocutaneous albinism, a pigment disorder caused by mutations associated with a
single N-linked glycoylation site within the Tyrosinase enzyme, a critical component of
the melanin biosynthesis pathway [250]. Conversely, mutation of the glycosylation sites
in horse radish peroxidase changing the asparagine to aspartic acids have been shown to
increase its heat stability and enzymatic activity, indicating that alterations in glycosylation
site number can also lead to increased function or stability [251].
The nature of glycosylation modification of proteins, as distinct from variation in
glycosylation site number, is extremely diverse and widely reported to affect protein
function, through contributions to protein folding and quality control as well as roles
in many biological recognition events [252]. This understanding that glycosylation can
impart an additional layer of information content to polypeptide sequences has led to
the rise of the fields of glycobiology and glycomics. The role of glycosylation as an extra
layer of information is widely investigated in the field of immunoglobulin research where
glycoform variation is known to have an effect on the functionality of monoclonal antibody
therapeutics [253]. Moreover glycosylation patterns of the endothelium are believed to
represent specific homing patterns that identify different locations in the vasculature
[254]. Recently, variation in glycosylation modification has been correlated with disease
pathogenesis and as such its potential as a biomarker for a given physiological state of
disease is of increasing interest [255, 256]. The predictive power of hyper-glycosylated
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human choriogonadotrophin (CG) was also recently examined [257]. Consequently, there
have been calls for the development of glycoproteomics and systems glycobiology, though
these are currently limited by technology [256, 258]. At present no data exists on the
glycoforms of PSGs present endogenously, due to the inability to sufficiently purify PSGs,
collectively or individually, from biological samples for characterisation.
However, the effects of broad glycoform variation on PSG function were investigated by Ha
et al. using different recombinant protein expression systems [154]. The authors utilised
mammalian and bacterial expression systems, as well as enzymatic removal of glycosylation
to investigate the effect it has on the abilty of murine PSG17 to bind its receptor, tetraspanin
CD9. It was shown that bacterially produced PSG17 did not bind CD9. It was also shown
that mammalian PSG posessed terminal sialic acid modification, a modification insect cell
expression systems cannot produce. Interestingly,however, production of PSG17 in insect
cells did not affect its ability to bind CD9. Nor did it affect the reported ability of PSG17N to
induce a TGF-β1 response. However, a mammalian expression system is required to ensure
as near to what is understood to be correct glycosylation of the proteins as is possible. While
it is known that there exist differing glycosylation patterns between mammalian, yeast and
insect cells, it has only recently started to come to light that there may be biologically
significant differences between commercially utilised cell lines such as HEK and CHO
cells [259]. The choice of mammalian expression system has also been proposed to be of
relevance to the functionality of the resultant recombinant PSG by altering its affinity for
its receptor/s at the cell surface. Sulkowski et al. demonstrated that PSG17N and PSG23N
from CHO-K1 cells and HEK293T cells have different affinity for L929 cells which the author
proposes to be as a result of differing glycosylation patterns between the two cell types used
for production of the proteins [171].
Thus, it is concluded that glycosylation modifications of PSGs could play a role in modifying
their affinity for their receptors/the cell surface. Furthermore, much evidence has been
gathered implying an important functional role for the N/N1 domains, and some specific
residues within these domains, of PSGs in their ability to induce a cytokine response from
the listed responsive cell types. However, little work has been done to elucidate a role, if
any, for the IgC-type domains of the PSGs in this important aspect of their biology. Shanley
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et al. attempted to approach this question of functionality of PSG IgC-type domains in a
platelet-fibrinogen interaction assay when investigating the anti-platelet properties of PSGs
[180]. It was shown that a mutant PSG1 protein lacking the N-domain still retained full
functionality in this assay. This implied that multiple domains of PSGs, specifically PSG1,
possess biological activity in this assay. In light of this finding the KGD tri-peptide, perhaps
concluded pre-maturely to be unimportant for PSG1 function in earlier cytokine release
studies, requires re-investigation in a PSG1 N-domain only construct to rule out the activity
of other domains as confounding factors. Furthermore, the functionality of the remaining
domains is also in need of investigation.
In addition to the requirement for the investigation of the functional elements within PSG1,
the signalling underpinning the immunomodulatory functions of the hormone are in need
of greater elucidation. Ha et al. demonstrated that PSG17N induction of IL-6 and IL-10 was
PKA dependent [153]. Beyond this there has been no investigation of the signalling following
PSG1 treatment of immune cells.
3.2 Objectives and Outcomes
This chapter had two broad areas of investigation; the first was the study of the functional
importance of domains and motifs within PSG1 for the hormones expression, cytokine
induction and regulation of LPS-induced cytokines. There is a dearth of knowledge on the
functionality of the various domains of PSGs in humans. As such, a previously published
expression system for recombinant PSG generation was examined for suitability for study
in cytokine induction assays. In addition, a mutational approach was undertaken that
involved the deletion of the domains individually as well as attempts at their production
independently of one another. It was found that PSG1 induced TGF-β1 in a multi-domain
manner, that was not KGD or glycosylation dependant for the N-domain. Furthermore, the
deletion of the N-domain from PSG1 had no effect on PSG1 attenuation of LPS-induced
chemokine Cxcl2 from a mouse macrophage cell line. The induction of TGFB1 mRNA
was examined and only found in monocytic THP-1 cells indicating that the major source
of TGF-β1 is latent particle release from cellular stores. It was subsequently found that
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TGF-β1 contaminates preperations of PSGs from mammalian cells [260]. Size Exclusion
Chromatography (SEC) was utilized to remove the contaminating TGF-β1 from our protein
and PSG1 was shown to, in fact, not induce TGF-β1 release in the monocytic cells utilised
in this study. Sequential ablation of glycosylation sites within PSG1N had a negative effect
on PSG1N expression that was additive. Moreover, it was found that deletion of the N61 site
had the most significant impact of protein expression. Furthermore, forced introduction of
this site into a novel PSG9N protein rescued the expression of the protein.
The second area of investigation was the immunomodulatory role of PSG1. This was
examined through cytokine expression and release studies in monocytic and macrophage
cells. The only investigation into the signalling underpinning PSG1 function was by Ha et al.
who found that PSG17N induced Il-6 and IL-10 was PKA dependent [153]. In contrast, here it
was found that PSG1 pre-treatment attenuated LPS-induced TNF-α and IL-6 in mouse and
human monocytic and macrophage cells and that this was not PKA dependent. In addition,
and in contrast to Blois et al., it was found also that inhibition of TGF-β1 signalling did not
affect this [260]. Moreover IL-6 and IL-10 induction in response to PSG1 treatment could
not be detected. The status of the key NFκB regulator, IκBα was also investigated in PSG1
pre-treated LPS-challenged cells to see whether an alteration in NFκB regulation could be
detected. No effect could be observed.
3.3 Results
3.3.1 Validation of protein production, and function in TGF-β1 induction assay
The transient Freestyle™293 mammalian protein expression system was chosen to study
PSG functionality as it was amenable to the generation of a series of mutants without
the requirement for the establishment of stably over-expressing cell lines. It was first
investigated whether it was possible to generate pure PSG in sufficient quantities for
functional studies.
Figure 3.1(A) shows the chromatogram from a nickel agarose affinity chromatography
column of beads that had been batch-bound overnight in PSG-containing medium
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supplemented with 10 mM Imidazole and eluted with indicated washes of increasing
imidazole concentrations. This indicates that large quantities of protein remains attached
to the Ni-NTA beads through the exstensive volumes of washes. Note, also, that the elution
of protein from the beads gives a peak in absorbance in the 200 mM fractions. The
increasing imidazole concentration starts to reach background column eluate absorbance
in the 300 mM range. Fractions were seperated by SDS PAGE and the elution pattern of the
recombinant PSG1 visualized by coomassie staining (Fig. 3.1(B)) . Most of the recombinant
PSG1 elutes in the 50 and 200 mM fractions. The indicated fractions were pooled and
processed further as indicated and described in the materials and methods chapter. 2 µg
of the resultant protein was separated by SDS PAGE and visualized by coomassie staining
to examine purity. Figure 3.1(C) demonstrates that the PSG1 generated for this study is >
95% pure as determined by densitometric analysis of the coomassie stained gel as outlined
in the materials and methods.
A further requirement for this study is that the protein production process be endotoxin
free. To that end a series of batches were tested for LPS contamination and demonstrated
to be endotoxin free by LAL assay (Lonza biosciences, UK) confirming that our reagents,
disposable plasticware and production system generated endotoxin free product. It was
also necessary to determine fully the processing that happened to the primary translated
protein sequence and whether the initial Signal-P v4.1 predicted 34 amino acid signalling
peptide was indeed cleaved [261]. A sample of frozen aliquoted PSG1 was sent to be N-
terminally sequenced by Edman degredation (Alta-biosciences, UK). This yielded a 5 amino
acid sequence corresponding to the N-terminus of the secreted purified PSG1. The amino
acid sequence ’VTIEA’ reveals that the secretion process in fact cleaves a 35 amino acid
peptide from the N-terminus of PSG1 (Fig. 3.2). This was also confirmed to be the case
with protein made from two endogenous splice variants of mouse PSG22 (Williams, J.
unpublished).
The protein generated through this system was previously demonstrated to have biological
function in a platelet-fibrinogen interaction assay [180]. This study aimed to investigate
the function of these proteins in cytokine induction assays. As mentioned earlier, several
publications provide evidence that PSGs induce the release of cytokines from various cell
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types. As a further control for the effects of non-specific contaminants of the purification
process a protein control was required that could be used as a negative control for functional
analysis of PSG1. The closely related membrane bound CEACAM1 was mutated by PCR
to remove the hydrophobic membrane targeting sequence and subcloned into pTT3 as
described in the materials and methods, incorporating a C-terminal V5-His tag. This
construct was sequenced and verified to contain the CEACAM1 protein coding sequence
in frame incorporating the tag sequence. The protein, designated CEACAM1∆TM, was
expressed as described and purified in a similar fashion to PSG1. Figure 3.3 (A) shows the
chromatogram of 1.5 ml imidazole fractions from the CEACAM1∆TM bound nickel agarose
beads. The fractions were resolved by SDS PAGE and the resultant protein is indicated
(Fig. 3.3 (B) and (C)). Interestingly this protein was smaller than previously published
reports examining soluble CEACAM1 proteins. Critically, the protein was larger than PSG1
and showed significantly more glycoform variation. The size difference between PSG1 and
soluble CEACAM1 is due to the greater amount of predicted glycosylation sites found in
CEACAM1. We hypothesize that the predicted glycosylation sites were not all modified in
our expression system yielding a lower molecular weight CEACAM1∆TM protein. The role
of this recombinant protein as a negative control for the purification process can still be
carried out.
Pregnancy Specific Glycoprotein Function,
Conservation and Receptor Investigation
58 Ronan T. O’Riordan
3. MUTATION OF PSG1 AND ANALYSIS OF ITS
IMMUNOMODULATORY FUNCTION 3.3 Results
FractionsW
1
W2 W4W3
50
.1
50
.2
50
.3
50
.4
20
0.1
20
0.2
20
0.3
20
0.4
20
0.5
30
0.1
30
0.2
30
0.3
50
0.1
50
0.2
50
0.3
175
80
58
46
30
25
17
KDa
Pool fractions, 
concentrate, 
dialyze x 3
A
B
C
Imidazole
PSG1 Eluate
2.5
2.0
1.5
1.0
0.5
0
A
bs
or
ba
nc
e 
 
λ2
80
58
80
175
46
30
25
17
KDa
Figure 3.1: Purification of recombinant PSG1 protein
(A) Chromatogram of 1.5 ml washes and imidazole elutions of PSG1 from nickel agarose
affinity column. (B) Coomassie stain of 22.5 µl of highlighted fractions separated by 10 %
SDS PAGE. (C) Coomassie stain of 2 µg of PSG1 resulting from processing of fractions.
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Figure 3.2: N-terminal protein sequencing of PSG1 confirms 35 amino acid signal peptide
cleavage
PSG1 protein sequence was applied to the SMART at EMBL which utilizes the Signal-P
signal peptide prediction algorithm to determine signal peptide cleavage[262, 263]. This
predicted a 34 amino acid signal peptide in PSG1. N-terminal sequencing revealed the first
five residues of the processed and secreted protein showing that 35 amino acids had been
cleaved.
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Figure 3.3: Purification of recombinant CEACAM1∆TM protein
(A) Chromatogram of 1.5 ml washes and imidazole elutions of CEACAM1∆TM from nickel
agarose affinity column. (B) Coomassie stain of 22.5 µl of highlighted fractions separated by
10 % SDS-PAGE. (C) Coomassie stain of 2 µg of CEACAM1∆TM resulting from processing of
fractions.
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In response to 24 hr treatment with increasing concentrations of PSG1 protein, monocytic
THP-1 cells release TGF-β1 over CEACAM1∆TM control treated cells (Fig. 3.4 (A)). Other
previously reported responsive cell types, HUVEC-2 human endothelial cells and murine
macrophage cell line, RAW264.7, also demonstrated PSG1 induced TGF-β1 release (Fig. 3.4
(B) and (C)).
The method by which PSG1 regulates TGF-β1 was examined further by looking at the mode
of induction of TGF-β1 that PSG1 elicits from several cell types by qRT-PCR and ELISA. I
found that PSG1 produces significant induction of TGFB1 mRNA in monocytic THP-1 cells
but, interestingly, not in the PMA-differentiated macrophages derived from these cells or the
endothelial HUVEC-2 cell line (Fig. 3.5 (A)). The release of TGF-β1 could be detected from
as early as 1 hr in the media of all cells tested, indicating that PSG1 is causing the release of
latent TGF-β1 from cellular stores as the main means of inducing the cytokine (Fig. 3.5 (B)).
The induction of TGFB1 mRNA observed in monocytes, taken with the lack of induction in
the other cell types tested indicates that this result is most likely a cell or cell line specific
and would need further investigation.
I also investigated whether IL-10, a previously reported PSG-induced cytokine, could be
detected following PSG1 treatment of monocytic THP-1 cells. IL-10 release could not be
detected in the supernatant of cells treated with PSG1 at all time points tested from 6-24 hrs
as determined by ELISA. We further examined IL10 gene expression by qRT-PCR however
there is no significant upregulation (Fig. 3.5 (C)). Interestingly, LPS also did not induce il-
10 transcription or protein release in the systems tested indicating that perhaps the cells
are LPS insensitive or the cell system was not competent for studying IL-10 release and
regulation by PSG1. Having established the baseline regulation of TGF-β1 and being unable
to replicate previously reported IL-10 induction, I determined to use TGF-β1 induction as a
measure of PSG1 activity for subsequent functional tests on mutant PSG1 constructs.
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Figure 3.4: PSG1 induces TGF-β1 in a dose dependant manner from previously reported
responsive cell lines
(A) TGF-β1 release from 24 hr PSG1 treated THP-1 cells was measured by ELISA and showed
a dose-dependant response to PSG1 treatment over CEACAM1∆TM protein control. 50
µg/ml, equivalent to approximately 1 µM, PSG1 treatment of HUVEC-2 endothelial cell
line (B) and RAW264.7 murine macrophage cell line (C) show that PSG1 induces TGF-β1
from other previously reported responsive cell types. n=3, Two-way ANOVA with Bonferroni
post-test.
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Figure 3.5: PSG1 regulation of TGF-β1 and IL-10
(A) qRT-PCR analysis of TGFB1 expression in 50 µg/ml PSG1 or 100 ng/ml LPS treated
monocytic THP-1, PMA-differentiated THP-1 and HUVEC-2 endothelial cells shows gene
expression is only significantly upregulated in monocytic THP-1 cell line. (B) Analysis of
release of TGF-β1 into the media in the same samples by ELISA shows that it is induced to
significant levels from as early as 1 hr in all cells tested. (C) Analysis of IL10 expression in
monocytic THP-1 cells shows that no significant expression could be detected in response to
PSG1 treatment. IL-10 could not be detected by ELISA in any samples tested. n=3, Two-way
ANOVA with Bonferroni post test.
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3.3.2 Multiple domains of PSG1 induce TGF-β1 release
As the IgV-type N/N1 domains of human and murine PSGs have been so heavily studied
for their ability to induce cytokine release, it was decided to employ a previously generated
PSG1 mutant lacking the N domain [180], PSG1∆N, to the TGF-β1 release assay to determine
if the PSG1 IgC-type domains also induce its release. Figure 3.6 demonstrates that PSG1∆N
does still induce TGF-β1 release. In addition, this lack of a requirement for the PSG1 N-
domain was observed in the newly identified ability of PSG1 to attenuate the LPS-induced
expression of the chemokine Cxcl2 in the RAW264.7 murine macrophage cell line (Fig.
3.7). Thus, it is concluded that the N-domain, though sufficient, is not in fact necessary
for PSG1 induction of TGF-β1 release or for attenuation of LPS-induced chemokines by
PSG1. This raises questions about much PSG1 research where point mutations of individual
residues of PSG1 N-domains, in the context of the full length protein, may have led to
premature conclusions on the functional importance of these residues. It may be required
that mutations in the N-domain be studied in an N-domain-only context to draw firm
conclusions as to their importance. Moreover it identifies the functional importance of the
remaining the domains of the PSG1 molecule.
Subsequently a further domain was deleted from PSG1∆N generating a novel construct
encoding both the PSG1 A-domains, PSG1A1A2, and protein was successfully produced
(Fig. 3.8(A) and (B)). When tested in the TGF-β1 assay in equimolar treatments along with
PSG1 it was found that PSG1A1A2 induces significant levels of TGF-β1 release (Fig. 3.8(C)).
Thus, it is evident that there is TGF-β1-releasing activity in the A domains of PSG1.
To further refine our understanding of the remaining domains of the PSG1 molecule it was
decided to generate constructs designed to express individual A1, A2 and B2 domains of
PSG1. Figure 3.9(A) shows anti 6xHis western immunoblot of cell lysates and supernatants
from transient transfection of Freestyle™293 cells with pTT3 constructs encoding the
individual domains of PSG1. These indicate that PSG1N, as previously reported, is
successfully expressed and secreted, as are PSG1A1 and PSG1A2. PSG1A1 and PSG1A2,
however, both show signs of degradation indicating that they may be unstable proteins.
PSG1B2, while showing expression at low levels, is not however secreted at detectable levels.
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Figure 3.6: PSG1 N-domain is not necessary for TGF-β1 induction
(A) Schematic showing domain structure and relative amino acid count of PSG1 and
PSG1∆N proteins. (B) Comassie stained 10 % polyacrylimide gel showing 2 µg of PSG1 and
PSG1∆N. (C) Monocytic THP-1 cells were treated for 24 hrs with 1 µM PSG. TGF-β1 release
was determined by ELISA. n=6, One-way ANOVA with Tukey post-test.
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Figure 3.7: PSG1 attenuation of LPS-induced cxcl2 is not N-domain dependant
RAW264.7 macrophage cell line was pre-treated for 10 mins with either PSG1 or PSG1∆N
and subsequently challenged for 3 hrs with LPS. cxcl2 expression was analysed by qRT-PCR.
n = 6, One-way ANOVA with Tukey post-test.
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Figure 3.8: PSG1A1A2 induces TGF-β1
(A) Schematic of PSG1 proteins used. (B) Coomassie stained polyacrylymide gel showing
2 µg of PSG1 and PSG1A1A2. (C) PSG induction of TGF-β1 release from monocytic THP-1
cells showing PSG1A1A2 induces significant levels the cytokine. n=3, Two-way ANOVA with
Tukey post-test. Samples were compared to PBS control.
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PSG1A1 and A2 were transfected into 100 mls of Freestyle™293 cells. The PSG containing
media was processed as normal. Fractions 50.4 - 300.1 were pooled, concentrated and
dialyzed but only minimal amounts of protein were recovered. To confirm protein was not
being lost, the fractions, the concentrated sample, and the centrifugal force spin column
flow-through were seperated by 12 % SDS PAGE, transferred to a membrane and probed
with an anti-6xHis antibody. Figure 3.9(B) indicates that small amounts of protein are
present in 50 mM fractions but not in sufficient quantities to make a significant difference
to overall protein recovery as they could only be detected by Western blotting. There also
appears to be two distinct species in the PSG1A1 sample, indicating that most likely proteins
are not stably expressed and are extremely unlikely to be recovered in sufficient quantities
to perform functional experiments.
As multiple individual domains of the protein cannot be independently produced to study
their function in inducing TGF-β1 release, it was decided to focus on the N-domain of the
protein since it is relatively better characterized and more mutations of this domain have
been published, which need re-examining in the N-domain only context.
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Figure 3.9: PSG1 individual A1, A2 and B2 domains cannot be purified
(A) Time course of transfections of Freestyle™293 cells with pTT3PSG1N, pTT3PSG1A1,
pTT3PSG1A2 and pTT3PSG1B2. (B) 22.5 µl of fractions and purified protein, as well as
flow through from centrifugal force spin column were probed for presence of recombinant
protein with anti 6xHis antibody.
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3.3.3 Mutation of a conserved RGD-like tri-peptide does not affect PSG1 N-
domain function
Primate N- and rodent N1-domains contain a conserved RGD-like tri-peptide that has been
proposed to have a role in their function [81]. It was observed that PSG1 differs slightly
in that it has a GDD tri-peptide in this position but one position back, the presence of
a lysine (K) gives PSG1 a KGD tri-peptide sequence on the solvent exposed loop of its
N domain. This motif is found in snake venom disintegrins like barbourin. Work from
our group demonstrated that mutation of the KGD tri-peptide sequence from PSG1N to
AAA does not affect the function of the domain in a series of platelet integrin-fibrinogen
interaction assays. Ha et al. demonstrated that a PSG1 GDD→SDL mutation did not affect
PSG1 induced TGF-β1 release a result confirmed with our PSG1 KGD→AAA mutant (Fig.
3.10(A) and (B)) [155]. This, however, must be revisited in the context of the earlier findings
of this chapter that demonstrate the mutli-domain functionality of the PSG1 molecule, with
a focus on the N-domain specifically. Figure. 3.10 (C) and (D) demonstrates that mutation
of the KGD tri-peptide from the PSG1 N-domain also does not affect the ability of this
domain to induce TGF-β1 release from THP-1 cells confirming that the KGD tri-peptide is
not essential for this function of PSG1.
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Figure 3.10: Mutation of KGD tri-peptide does not affect PSG1 or PSG1N induced TGF-β1
release
(A) Coomassie stained polyacrylymide gel showing 2 µg of PSG1 and PSG1 KGD→AAA.
(B) Monocytic THP-1 cells were treated for 24 hrs with 1 µM PSG. TGF-β1 release was
determined by ELISA. (C) Coomassie stained polyacrylymide gel showing 2 µg of PSG1N
and PSG1N KGD→AAA. (D) Monocytic THP-1 cells were treated for 24 hrs with 1 µM PSG.
TGF-β1 release was determined by ELISA. n=3 both mutants, One-way ANOVA, with Tukey
post-test.
Pregnancy Specific Glycoprotein Function,
Conservation and Receptor Investigation
72 Ronan T. O’Riordan
3. MUTATION OF PSG1 AND ANALYSIS OF ITS
IMMUNOMODULATORY FUNCTION 3.3 Results
3.3.4 Glycosylation site number alteration negatively affects PSG secretion
An interesting feature of the human, and other, PSG gene families is that there is variation
in predicted glycosylation site number between different family members. I investigated
if glycosylation site number variation could have functional consequences. First it was
necessary to examine, as reported for other proteins, whether glycosylation site number
variation could affect secretion of the PSG. To that end, the PSG1N construct was mutated
to remove all the glycosylation sites individually and in pairs and to examine the expression
and secretion of these mutants in Freestyle™293 cells by western immunoblot. The choice
of the PSG1N protein as a model had the double benefit of reducing the number of mutants
it was necessary to generate, while also making it more likely that the negative affects of the
mutations would be more easily observed due to the mutant nature of PSG1N. Alteration of
the asparagine (N) in the N-Xaa-S/T glycosylation site consensus sequence to an aspartic
acid (D) removes the substrate for the attachment of the glycosidic bond while inserting
an amino acid with a similar charge to the glycosylated asparagine, recapitulating the
deamination reaction that occurs through PNGaseF.
Figure 3.11 shows that deletion of an individual site negatively affects secretion and that
this effect is additive. Interestingly, constructs lacking the N61 glycosylation site seem to
be the most negatively affected indicating that this site might more fundamentally affect
protein stabilty and expression than other sites. This is in keeping with observations
in other proteins that the more N-terminal a glycosylation site is, the more it can
affect stable expression and secretion of recombinant proteins, as was shown for von-
Willebrand factor [264] . Thus PSG1N expression responds negatively to alterations in its
glycosylation pattern. As an additional experiment a construct encoding PSG9N, which
was generated but abandoned due to the inability to express the protein successfully, was
utilised to examine whether introduction of the N61 glycosylation site consensus sequence,
which is endogenously lacking in PSG9 as well as PSG3, PSG4, PSG5, and PSG11, could
rescue the expression and secretion of the protein. A PSG9NP63T mutant which has
the N61 glycosylation consensus sequence was generated and examined for expression
and secretion in Freestyle® 293 cells. Figure 3.12 demonstrates that introduction of the
glycosylation consensus sequence into PSG9N rescued protein secretion, indicating that
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this site is indeed important for secretion of the PSG N domain. It is unlikely that this site
is fundamental to PSG9 secretion as that protein expressed and was purified successfully
in Shanley et al. and later in this chapter, however lower yields were obtained compared to
PSG1 [180].
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Figure 3.11: Mutation of predicted glycosylation sites negatively effects PSG1N
expression and secretion
Anti-6xHis and β-actin immunoblots of Freestyle™293 cells transfected with glycosylation
mutant constructs of PSG1 N-domain. 60 µg lysate and 45 µl of supernatant were loaded
into the wells for each sample.
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Figure 3.12: Restoration of a glycosylation consensus site in PSG9N rescues protein
expression
Anti-6xHis and β-actin immunoblots of lysates and cell culture supernatnants from
Freestyle™293 cells transfected with pTT3PSG9N and pTT3PSG9N P63T constructs show
P63T mutation rescues secretion of PSG9N. 50 µg lysate and 22.5 µl of supernatant were
added for each sample.
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3.3.5 Glycosylation site number alteration does not affect PSG induced TGF-β1
release
PSG4 and PSG9 proteins were generated as described in the materials and Methods
(Fig. 3.13(A)). While all PSG family members tested induced TGF-β1, an observation was
made that members of the gene family with reduced predicted glycosylation site number
demonstrated significantly increased induction of TGF-β1 release (Fig. 3.13(B)). As the
PSG4 and PSG9 preparations were of lesser purity to PSG1, further investigations were
required to implicate glycosylation site number variation in PSG-TGF-β1 induction.
To that end it was undertaken to mutate the variable (N61) and one of the conserved
(N111) glycosylation sites of the human PSG N-domains in the context of the full length
PSG1 protein. As previously outlined the mutation was N→D abolishing the site for the
attachment of the glycosidic bond. Fig. 3.14(A) shows the resultant proteins. PSG1 N61D
shows a marginally lower molecular weight on the gel in comparison to the other proteins.
However when proteins were examined for ability to induce TGF-β1 release in it was found
that no significant difference could be observed between the mutants and the wildtype. This
would appear to rule out any major functional role for glycosylation site number variation
within the PSG N domains in induction of TGF-β1 release. However to conclusively prove it
was again necessary to ask the question in an N-domain only context where any differences
are free from potential confounding impacts of the remaining domains and functional
effects could likely be more easily observed. Thus the previously generated mutants of
the PSG1N protein, PSG1N N61D and PSG1N N111D were utilised to generate proteins for
functional studies.
Both PSG1N N61D and PSG1N N111D could be produced in sufficient quantities for
experimentation, though lower yields were obtained for PSG1N N61D (data not shown).
When examined for purity by 12 % SDS PAGE and coomassie staining it was found that
both glyco mutants had a lower molecular weight than the PSG1N and PSG1N N111D
had a tighter band compared to PSG1N indicating reduced glycoform variation, as would
be expected (Fig. 3.15(A)). Interestingly, PSG1N N61D had a larger amount of glycoform
heterogeneity, however this is not conclusive as the pattern on the gel could equally be as
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a result of degradation due to reduced protein stability. An attempt was made to further
purify the proteins by Size Exclusion Chromatography (SEC) on a Superdex 75 column. The
resultant proteins showed significantly less contaminating high molecular weight bands,
though some were still present (Fig. 3.15(B)). These proteins were tested in the TGF-β1
induction assay and Fig. 3.15(C) shows that glyscosylation site mutation does not affect
PSG1N domain-induced TGF-β1 release.
Pregnancy Specific Glycoprotein Function,
Conservation and Receptor Investigation
78 Ronan T. O’Riordan
3. MUTATION OF PSG1 AND ANALYSIS OF ITS
IMMUNOMODULATORY FUNCTION 3.3 Results
B
A
175
80
58
46
30
25
17
PS
G1
PS
G4
PS
G9
TG
F-
β 1
 (p
g/
m
l)
2500
0
2000
1500
1000
500
Un
tre
ate
d
PB
S
PS
G1
PS
G4
PS
G9
KDa
Figure 3.13: PSGs 4 and 9 induce significantly more TGF-β1 release compared to PSG1
(A) Coomassie stained polyacrylymide gel showing 2 µg of PSG1, PSG4 and PSG9. (B) PSG
induction of TGF-β1 release from monocytic THP-1 cells showing PSG4 and PSG9 induce
significantly more compared to PSG1. n=3, One-way ANOVA with Bonferroni post test.
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Figure 3.14: Deletion of conserved or variable glycosylation sites does not affect PSG1
TGF-β1 induction
(A) Coomassie stained polyacrylymide gel showing 2 µg of PSG1, PSG1 N61D and PSG1
N111D. (B) Treatment of HUVEC-2 endothelial cells with 50µg/ml PSG shows no significant
difference between mutants in their ability to induce TGF-β1 release. n=3
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Figure 3.15: Glycosylation site number does not affect PSG1 N-domain TGF-β1 induction
(A) 3 µg of indicated PSG1N proteins. (B) Same proteins after further purification by SEC
using an S75 prep grade size exclusion column. (C) 50 ug/ml treatment of THP-1 cells with
PSG1N, 1N N61D and 1N N111D for 24 hrs shows all induced significant levels of TGF-β1
release with no significant difference between mutants observed. n=3, One way ANOVA
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3.3.6 Reported PSG1-induced TGF-β1 release as a result of contamination from
mammalian culture expression system?
Thus far, all mutants examined appeared to be incapable of ablating PSG1-induced TGF-
β1 release, negating fundamental roles for the N domain or its constituent conserved
KGD/RGD tri-peptide or its conserved/variable glycosylation sites in this reported function
of PSGs. However, a number of interesting observations were made at this point of the
research into PSG function. Firstly, the level of variation in TGF-β1 induction between
batches of proteins used throughout the course of this work was considered to be large
in comparison to the published literature [153, 154, 158, 155, 170, 171, 156]. Secondly,
the variation in TGF-β1 induction between members of the same family (PSGs 1, 4 and 9)
was larger than anticipated given their sequence similarity and was observed for PSG23
as well (data not shown). Taken in the context of an inability to knockout the function
under investigation I became concerned that, in spite of the wide body of literature in
support of the finding, the examined release of TGF-β1 in response to PSG treatment may
be artefactual.
A subsequent personal communication from Prof. Gabriela Dveksler indicated that there
may be evidence for an interaction between PSG and TGF-β1 in that TGF-β1 (latent and
active) appears to contaminate the PSG produced in mammalian cell expression systems
utilised in previous studies [153, 154, 158, 155, 170, 171, 156]. A publication followed which
demonstrated the contamination and furthermore outlined a role for PSG in activating
latent TGF-β1 [260]. This represented a major confounding factor for much of the functional
work preceeding this point in the chapter.
Finally, a publication from the end of 2012 showed that the widely used immobilised metal
affinity chromatography (IMAC), which is employed in this study and several of the PSG-
related publications with TGF-β1 contaminated protein, co-purifies TGF-β1 from HEK293
cells based on a specific interaction between the immobilized metal ions and TGF-β1 [265].
As this would represent a further confounding factor, PSG1 utilised in this chapter was
investigated for TGF-β1 contamination. Following on from this it was decided to investigate
if, as in Kaur et al., SEC could be utilised to remove the contaminating TGF-β1 [265].
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Figure 3.16 (A) shows that TGF-β1 does contaminate PSG1 purified from Freestyle™293
cells utilising nickel agarose beads, however, the levels of TGF-β1 vary dramatically and
are entirely composed of the latent particle. Active TGF-β1 is probably removed during
the concentration step in the purification protocol which utilises 30 kDa MWCO ultra-
centrifugal force filters. This is important as the lack of active TGF-β1 precludes any
signalling events being induced by this potent signalling molecule, which could confound
any functional work on the immunological or angiogenic roles of these hormones. However
the presence of latent particle in such quantities in some preparations represents an
obvious potential confounding factor and highlights the need for a second round of
purification. The authors of the aforementioned study identified high salt gel filtration
as an effective means of removing TGF-β1 from the purified recombinant protein utilised
in their study. As such, gel filtration chromatography was employed to determine if the
TGF-β1 contaminant could be removed. Figure 3.16 (B) shows the chromatogram of PSG1
applied to a HiLoad 16/60 Superdex 200 prep grade column using an Akta explorer system.
The peak fractions pooled are indicated in Figure 3.16 (C) and the resultant proteins were
seperated by 10% SDS PAGE followed by coomassie staining (Fig. 3.16(D)). The staining
pattern indicated that the gel filtration removed high molecular weight contaminants. TGF-
β1 ELISA analysis of the proteins demonstrated the the system was effective at removing
theTGF-β1 contamination from the PSG1 protein (Fig. 3.16 (E)). Interestingly, high salt
buffer was not required in contrast to Kaur et al. [265]. Finally, SEC-purified protein was
applied to HUVEC-2 endothelial cells, reported in the literature and earlier in this chapter,
to release TGF-β1 in response to PSG1 treatment. Figure 3.16 (F) shows that PSG1 does not,
in fact, induce release of TGF-β1 as previously reported.
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Figure 3.16: PSG1 does not induce TGF-β1 release
(A) Large batch to batch variation detected in amount of TGF-β1 contaminant in PSG1.
Chromatogram from PSG1 applied to a Superdex 200 prep grade size exclusion column
with red box indicating area of interest (B) from which fractions representing two peaks
were seperated and pooled (C). (D) Coomassie stained 10% polyacrylymide gel with 8 µg
of indicated protein per lane. (E) TGF-β1 ELISA indicating that SEC removed latent TGF-
β1 contaminant. (F) SEC purified PSG1 does not induce TGF-β1 release from HUVEC-2
endothelial cells, n=3. SM, Starting Material.
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Thus having ruled out TGF-β1 as a reliable readout of PSG1 function, it was decided to
focus on its immunomodulatory properties by examining whether PSG1 could affect the
expression of pro-inflammatory cytokines induced by LPS stimulation of leukocytes. As
outlined earlier, a novel finding was that PSG1 could attenuate LPS-induced Cxcl2 from the
RAW264.7 macrophage cell line and that this was not N domain dependant (Fig. 3.7). It was
aimed to determine whether other pro-inflammatory cytokines could be attenuated in this
way and whether the signalling mediating this could be elucidated.
TGF-β1 is an obvious signalling candidate for many reasons. The earlier described
contaminant though composed almost entirely of the latent particle does not preclude the
activity of pg amount of active TGF-β1 present. In addition, the proposed novel function
ascribed by Blois and colleagues , whereby PSG1 binds and activates TGF-β1, requires that
it is investigated here [260]. In the same paper, though in lymphocytes, the effects being
examined here of attenuation of pro-inflammatory cytokines, were shown to be TGF-β1-
dependant by application of a TGF-β1 neutralising antibody. Furthermore, TGF-β1 has
recently been demonstrated to have a role in the regulation of genes necessary for the full
polarization of macrophages to an M2 phenotype [266].
3.3.7 PSG1 attenuates LPS-induced pro-inflammatory cytokine expression and
secretion independant of TGF-β1 and PKA signalling
Early on in our studies of PSG function it was found that IL-10, previously reported to be
induced by PSG1, could not be found to be induced in response to our protein in the cell
systems tested while a small induction was observed at the transcriptional level (Fig. 3.5). It
was, however, noted that it was not possible to detect il-10 in the LPS positive control either.
Due to the widely acknowledged ability of cell-line systems to become LPS insensitive, a
new stock of THP-1 cells were purchased to re-examine the immunomodulatory capacity
of PSG1. It was found that co-treatment with 1 µM PSG1 (50 µg/ml) and low dose LPS (1
ng/ml) had opposing effects on LPS-induced il-10 and il-6 expression in PMA-differentiated
THP-1 cells. A very small additive effect on il-10 expression was observed associated
with an attenuating effect on LPS induced il-6 and tnf-α (Fig. 3.17). No induction of
il-6 from PSG1 treatment alone could be detected contrary to previous reports for PSGs
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[149, 153, 157]. However this could be a cell line-specific effect. Taken together these data
indicate a pattern of differential gene regulation consistent with an M2 polarising effect
of PSG on monocytes/macrophages where immunosuppressive cytokines such as IL10 are
upregulated in inflammatory situations and pro-inflammatory cytokines are attenuated.
It was next aimed to examine this effect on LPS induced IL-6, TNF-α and IL-10 at the protein
level in primary bone marrow derived macrophages (BMDMs) using higher doses of LPS,
and PSG1 at endogenous levels of approximately 250 µg/ml, or 5 µM. It was observed that
while there is a trend of attenuation for all samples, it is significant only for IL-6 when
compared to the PBS control in the 10 and 100 ng/ml LPS samples at 6 hrs Fig. 3.18. IL-
10 could not be detected in any samples tested indicating that this cell system is likely not
suitable for studies of IL-10 induction.
Subsequently, the signalling mediating the observed attenuation was investigated by using
small molecule inhibitors against candidate signalling pathways that could be implicated in
this function of PSG1. As already outlined TGF-β1 represents a good candidate for mediating
the pro-inflammatory cytokine attenuation of PSG1. A second candidate of interest was
cAMP-dependant PKA. PKA has been implicated in PSG17 induced up-regulation of IL-
6 and IL-10 [153]. While neither of these cytokines could be induced by PSG1 in this
study, it does not necessarily preclude PKA signalling as a candidate signalling pathway
mediating PSG1’s effects. cAMP has long been known to have an attenuating effect on
pro-inflammatory signalling in monocytes and macrophages [267]. More recently cAMP,
through PKA, has been shown to be able to illicit differential effects on genes controlled
through the same transcription factor, namely NFκB, by means of association with PKA
anchoring proteins [268]. Similarly, PKA mediated cross-talk with other TLRs has been
shown to be responsible for attenuating their pro-inflammatory signals through NFκB [269].
Therefore, given the pattern of differential regulation of LPS-induced NFκB regulated genes
that we are observing in response to PSG1 treatment, PKA is a good candidate signalling
pathway to be mediating this.
Two inhibitors were used for studying both candidate signalling pathways due to recent
publications outlining shortcomings and potential off target effects of the historically more
widely utilised H-89 and LY364947 [270, 271]. SB504124 is a more highly selective inhibitor
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than other TGFβRI inhibitors [271, 272]. PKI(6-22) is a palmitylated peptide analogue
specific for the cAMP binding pocket of PKA.
Critically no significant attenuation of TNFA or IL6 could be observed (Fig. 3.19). While
there was a trend of attenuation of IL6 which was not affected by either H89 or LY34, it is not
possible to draw solid conclusions from this. The SB50 inhibitor appeared to affect the LPS-
treated sample and as such it is believed further optimisation of the dose of this inhibitor
may be needed. No TNFA attenuation could not be detected. This is in keeping with the
earlier findings in BMDMs Fig. 3.18. In addition, IL10 expression showed no induction
in response to PSG1 however a large induction of IL10 was observed in the LPS-treated
samples indicating it is likely PSG1 does not directly induce IL10.
The convergence of multiple inflammatory receptor pathways on the NFkB pathway
confirms its importance to the regulation of the response to inflammatory stimuli [273].
It was finally aimed to investigate whether PSG1 could attenuate the pro-inflammatory
signal by affecting the degradation of IκBα. IκBα degradation induced by 1 µg/ml of LPS
is conserved in PSG1 treated THP-1 cells (Fig. 3.20).
Pregnancy Specific Glycoprotein Function,
Conservation and Receptor Investigation
87 Ronan T. O’Riordan
3. MUTATION OF PSG1 AND ANALYSIS OF ITS
IMMUNOMODULATORY FUNCTION 3.3 Results
Fo
ld
 C
ha
ng
e/
U
nt
re
at
ed
IL10
IL6
TNFA
2
0
4
6
8
10
Un
tre
ate
d
PS
G1
LP
S
Co
-tr
ea
t
0
10
20
30
40
50
60
70
Un
tre
ate
d
PS
G1
LP
S
Co
-tr
ea
t
Fo
ld
 C
ha
ng
e/
U
nt
re
at
ed
0
1
2
3
4
5
6
Un
tre
ate
d
PS
G1
LP
S
Co
-tr
ea
t
Fo
ld
 C
ha
ng
e/
U
nt
re
at
ed
Figure 3.17: PSG1 attenuates IL6 and TNFA expression but has additive effect on IL10
PMA-differentiated THP-1 cells were treated with PSG1at 50µg/ml. qRT-PCR analysis shows
that a small additive effect on il-10 expression was observed associated with an attenuating
effect on LPS induced il-6 and tnf-α. n=3, One-way ANOVA with Tukey post-test.
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Figure 3.18: PSG1 attenuates IL-6 and TNF-α release in mouse primary macrophages
BMDMs were pre-treated with 5 µM PSG1 for 30 minutes and subsequently challenged with
indicated dose of LPS for 6 hrs and 18 hrs. IL-6 and TNF-α release were determined by
ELISA. n = 6, Two-way ANOVA with Bonferroni post-test. Error bars are Mean and Standard
Deviation.
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Figure 3.19: TGF-β1 and PKA signalling can not be ruled out as mediating the observed
PSG1 mediated pro-inflammatory cytokine attenuation
Monocytic THP-1 cells were pre-incubated for 1 hr with PKA inhibitors, H89 [5 µM] and
PKI(6-22) [1 µM] as well as the TGFβRI inhibitors LY364947 [10 µM] and SB505124 [0.5 µM]
followed by 30 min 5 µM PSG1 treatment and subsequent 100 ng/ml LPS challenge for 3 hrs
before nucleic acids were harvested for qRT-PCR analysis of IL6, IL10 and TNFA expression.
No significant attenuation was observed, n=3, Two-way ANOVA
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Figure 3.20: PSG1 pre-treatment does not inhibit IκBα degradation
THP-1 cells treated for 12 hours with PSG1 or PBS control were chalenged with LPS for the
indicated times and lyzed to evaluate IκBα degredation by western immunoblot.
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3.4 Discussion
Several novel mutants were generated during the course of this research to study the
functionality of PSG1. It was aimed to investigate cytokines induced by PSG1 as well as
examining the expression and release of LPS-induced cytokines in PSG1-treated cells. It
was concluded that IL-6 and IL-10 could not be induced in response to PSG1, contrary to
previous reports for PSG1, PSG6, PSG11, PSG17N and PSG18 [149, 157, 153, 148]. This could
be a cell line specific effect or even due to the choice of cell line to produce the proteins for
this study. It has been reported that the choice of cell line in which PSGs are produced can
affect their function [171]. It was found that PSG1 induced TGF-β1 release and in a screen of
LPS-induced cytokines, suppressed Cxcl2 expression in a mouse macrophage cell line. Both
of these immunomodulatory functions were found to not require the N domain of PSG1
through application of a PSG1∆N mutant. To further study the functionality of domains and
residues in PSG1, it was decided to focus on PSG1-induced TGF-β1 release through testing
of the mutants in this assay, as this is a more widely reported PSG response.
However, after much of the work reported in this chapter had been completed, a
report demonstrating TGF-β1 contaminates proteins produced in HEK293 cells purified
by immobilised metal affinity chromatography (IMAC) was published [265]. This report
showed an interaction between the immobilised metal ions and the latent TGF-β1 particle.
Both the cell type examined as well as the purification process are applicable to work
in this chapter. Further to this, [260] demonstrated that PSG from different mammalian
expression systems and also endogenous PSG associate with TGF-β1 during different forms
of affinity chromatography. They also demonstrated that PSG1 activates TGF-β1 in a cell
free manner. We investigated this in our protein and it was subsequently found that latent
TGF-β1 contaminates the proteins used in this study and that after removal by SEC no
TGF-β1 induction could be found in response to PSG1 treatment. These publications and
our data raise serious questions about a number of earlier publications on PSGs as the
immunomodulatory and angiogenic functions ascribed to PSGs are possibly confounded by
the presence of TGF-β1. Equally, it is no longer certain whether PSG1 itself induces TGF-β1
or if it is solely an artefact of contamination. It was reported, however that the lymphocytes
isolated from PSG1 treated mice in [260] had higher cell surface levels of latent TGF-β1 as
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such it is still possible that PSG1 induces TGF-β1. Moreover, insect cell induced PSG1 will
be free from TGF-β1 and this has been reported to induce TGF-β1 [149].
While much of the functional data studying domains and motifs in the PSG1 protein in this
chapter are confounded by the discovery of a TGF-β1 contaminant at the end of the study,
much can still be inferred from the expression studies carried out on the individual domains
and the panels of glycomutants. Firstly, the inability to generate individual domains was
circumvented by generating the PSG1A1A2 domain protein. This is still a valuable tool that
can be used to study whether important functionality exists in the PSG1 N or B2 domains, if
utilised with the PSG1 and PSG1∆N proteins, as was attempted in this chapter.
During the study of the glycoylation sites of the PSG1 protein it was decided to focus again
on the more widely studied PSG1N protein. The effect that differences in glycosylation site
number can have on the expression and secretion of the PSG1N protein was examined as it
was a novel area yet to be examined in PSG research. Sequential mutation of glycosylation
sites has an additive negative impact on the secretion of the PSG1N protein. Interestingly
however, mutation of the N61 glycosylation site of PSG1N was shown to have a larger,
negative impact on secretion of the protein compared to the other single glycosylation
mutants. The was also true comparing the N61, 111D to the N104, 111D mutant. Thus, it was
concluded that the N61 glycosylation site makes a larger contribution to protein stability
and secretion than the other tested sites. The determination that mutation of most N-
terminal N-glycosylation site most negatively impacts protein expression and secretion has
been found for other proteins also [264]. As this site is absent in fully half of all human and
primate PSGs through alterations in the third amino acid of the consensus sequence, it was
decided to carry out the reciprocal experiment and introduce the glycoylation consensus
sequence into a novel PSG9N mutant through a P63T mutation. This introduced the
PSG1-like ’NLT’ amino acid sequence, and thus glycosylation at this site, in PSG9N. This
mutation rescued PSG9N secretion confirming the contribution that the most N-terminal
glycosylation site makes to PSG secretion. It must be noted, however, that the PSG9, and
PSG4, proteins can be succesfully expressed and secreted without this mutation, though
lower yields of protein are observed. This raises interesting questions about why this site is
then absent in half of human and primate PSGs. It is possible that the detrimental effects on
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secretion are balanced by an increase in activity as a result of the structural changes arising
from the incorporation of a proline or alanine at this site in the PSG N domain of those
proteins which do not possess the glycosylation consensus sequence. This glycosylation
site is located on the B-C loop of the protein, an area that shows significant variation in the
CEA family [75]. Importantly, this site is also absent in human CEACAM1 implying either
loss of this site from CEACAM1 subsequent to PSG radiation from the CEACAM gene family
or acquisition in the PSG family after this event. Moreover, it is also absent in mouse Psgs N1
domains except for Psg29 and PSG31 while the N104 and N111 sites are conserved. Further
research examining the evolution of this sequence could shed interesting light on PSG
function but also on the pressure driving evolution of both the PSG and CEACAM families.
In the second section of this chapter examining the immunomodulatory roles of PSG1, it
was demonstrated that the previously reported PSG-induction of IL-6 and IL-10 could not
be replicated at the protein level or transcriptional level. In fact, PSG1 attenuated LPS-
induction of IL-6 and TNF-α from monocytic and differentiated THP-1 cells, as well as
primary BMDMs at the transcriptional and protein levels. However there was not significant
attenuation in some experiments with results appearing to show variation based on cell
choice.
The abortogenic properties of TNF-α are widely acknowledged with high circulating levels
of TNF-α found in patients with miscarriages [274]. It has, however, been found that
while circulating levels of TNF-α are increased in the serum of preeclampsia patients,
that placental levels of the hormone show no difference between normal and preclamptic
patients, indicating a different source for the elevated levels of the cytokine [275]. As
already mentioned, low levels of PSG correlate with increased preecamplsia incidence as
well as higher levels of spontaneous abortion. The very high level of PSGin the serum could
potentially be to prevent the overexpression of TNF-α seen in preeclamptic patients that
could result from an over-active maternal immune response to pregnancy.
Increased circulating levels of IL-6 were also found in miscarriage patients [274]. A recent
review of the literature surrounding IL-6 in pregnancy outlines that elevated IL-6 has been
found in unexplained infertility, recurrent miscarriage, preeclampsia and preterm delivery
[276]. Moreover, IL-6 has been mechanistically implicated in the systemic activation of
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endothelium that is a hallmark of pre-eclampsia [277]. As already mentioned, these are all
disorders correlated with low levels of PSG. The same review highlights evidence indicating
"...altered systemic IL6 trans-signalling in women prone to recurrent miscarriage, with
excessive IL-6 bioavailability potentially inhibiting generation of CD4+ T regulatory cells
required for pregnancy tolerance". Thus PSG could very well contribute to the generation of
an environment that is more conducive to a successful pregnancy outcome by attenuating
systemic IL-6 and TNF-α with one of those effects being the increase of the generation of
Tr e g cells. Though not studied here, a number of groups have demonstrated a functional
role for PSG in this, in different immunological and physiological settings [157, 260]. Further
research is necessary to elucidate what mechanism is responsible for this.
The discovery of the presence of TGF-β1, as already outlined, represents a confounding
factor for much published PSG research directly for work investigating the reported
PSG-induced TGF-β1 release. Importantly, given TGF-β1s’ potent angiogenic and
immunomodulatory properties, it further represents a confounding factor for the previously
reported roles for PSG in these areas also. With regards to the study of immunomodulatory
functions attributed to PSGs in this work, it is relevant that active TGF-β1 is largely absent
from the proteins utilised in this study. This is likely as a result of the size cut off
during the concentration step of purification. However, the high doses of PSGs required
make micro-contaminants a concern. Moreover, it could not be ruled out that the large
amounts of latent TGF-β1 in some preparations of PSG1 were not being activated in
experiments. [260] also demonstrate the ability of PSG1 to attenuate IL-6 and TNF-α as
well as IFN-γ measured in lymphocytes isolated from a DSS-induced mouse colitis model.
Interestingly, they demonstrate this to be TGF-β1 dependant. To address this TGF-β1-RI
inhibitors were included in the experiments examining PSG1 attenuation of LPS-induced
pro-inflammatory cytokines in this chapter. While there was a slight trend for attenuation
of IL-6 in the THP-1 cells used there was no significant attenuation of pro-inflammatory
cytokines. Thus it was not possible to draw conclusions as to the roles of signalling pathways
in these effects.
It could not be demonstrated that TGF-β1 signalling is not having an affect on the
attenuation of pro-inflammatory cytokines by PSG1 in monocytic THP-1 cells. Moreover,
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the hypothesised role of PKA signalling could not be ruled out as contributing to this. It is
possible that differences exist in mechanisms of PSG1 action on myeloid and lymphocytic
cells. Further tests in more suitable cell lines are required.
In addition, to further examine the mechanism by which PSG regulated the induction
of LPS-induced cytokines, the levels and degradation pattern of a key regulator of NFκB
activity and localisation, IκBα, were assesed in untreated and PSG1 treated THP-1 cells.
It was found that LPS-induced degradation of IκBα were unaffected by PSG1 treatment,
implying that PSG1 must be regulating the expression of NFκB-regulated genes in a different
way. either through inhibition of this pathway downstream of IκBα or through the inhibition
of NFκB sites in these genes.
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Chapter 4
PSG1 is an integrinαVβ3 ligand
4.1 Introduction
The exact function of PSGs in normal pregnancy remains elusive but, as already outlined,
they have angiogenic, immunomodulatory and anti-platelet properties. The cell surface
interactions that mediate much of the functions of PSGs are incompletely understood. It
is known that both human and mouse PSGs have affinity for cell surface proteoglycan side
chains, specifically for syndecan family members and glypican-1 [158, 170, 156]. Mouse
Psgs have been shown to differentially bind tetraspanin CD9 while PSG1 has been shown
to not bind this receptor [150, 154, 158, 171]. The interaction of PSG17 with CD9 has
been demonstrated to mediate the cytokine induction from this PSG [153]. In addition,
it has been shown that the angiogenic properties of PSG1 require cell surface proteoglycans
[170]. In addition protein N-glycosylation has been demonstrated to affect the affinity of
recombinant PSGs for the cell surface [154, 171].
Integrins have been hypothesised by many to represent potential binding partners for
PSGs [179, 278, 81]. This has been largely due to the presence of a conserved proposed
integrin binding RGD-like tri-peptide motif in primate and rodent N and N1 domains
[81]. Moreover, the accumulating evidence for heperan sulphate proteoglycan (HSPG)
interactions with PSGs supports this, as these cell surface proteins, especially syndecans,
are known organisers of integrin activity and clustering at the cell surface, as is the case for
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integrins αVβ3 and αVβ5 in carcinoma and endothelial cells [279]. This is reviewed further
in [175, 178, 280]. Syndecans not only function as regulators of adhesion and migration
through modulation of integrin activity but also as docking receptors for a multitude of
extracellular ligand receptor interactions [280]. Syndecans can regulate extracellular events
without signalling to the cytoplasm through their protein core by binding and modifying the
bio-availability of ligands at the cell surface through their glycan sidechains [281, 177]. This
activity is seen in ligands such as fibroblast growth factor (FGF), vascular endothelial growth
factor (VEGF), epidermal growth factor (EGF), hepatocyte growth factor (HGF), platelet
derived growth factor (PDGF), and transforming growth factor b1 (TGFb1) which have been
shown to interact with and in may cases require syndecan glycan sidechains as well as their
cognate receptors [282, 283, 284, 285, 286, 287, 288]. PSG interaction with syndecans has
not been demonstrated to induce cell signalling events, thus it is possible that the binding
of PSG to the glycan sidechains of HSPGs serves a docking function.
PSG interaction with an integrin was demonstrated for the first time by [180] where
it was found that the interaction of PSG with the platelet integrin αIIbβ3 inhibited the
interaction between platelets and fibrinogen thus identifying a novel anti-platelet property
for PSGs. It is argued that this function could have evolved to "antagonise abundant (3
mg/ml) fibrinogen in the maternal circulation, which may be necessary to prevent platelet
aggregation and thrombosis in the prothrombotic maternal environment of pregnancy"
[180]. Interestingly this interaction was found to reside in multiple domains of PSG1 and
to occur independent of the solvent exposed N-domain KGD tri-peptide that PSG1 has in
common with some snake venom disintegrins [289, 180].
Even though the interaction of PSG1 with integrin αIIbβ3 was KGD independent,
nevertheless, a strong case exists for investigating other RGD-recognising integrins as
potential receptors for PSGs. Many RGD-recognising integrins are expressed on cells
types responsive to PSG or are to be found exposed to PSG contact in the vasculature
or the placenta as outlined in the introduction. These include integrins αMβ2, α5β1 and
αVβ3. Moreover there is evidence of interactions of RGD containing compounds with RGD-
recognising integrins in an RGD-independent manner, as is the case for tumistatin and the
integrin αVβ3 [290]. In addition, it has been demonstrated that blocking of integrin αVβ3 by
Pregnancy Specific Glycoprotein Function,
Conservation and Receptor Investigation
98 Ronan T. O’Riordan
4. PSG1 IS AN INTEGRIN αVβ3 LIGAND 4.2 Objectives and Outcomes
cyclic RGD inhibits the additive effect ligation of this integrin has on LPS-induced and TNF-
α-induced pro-inflammatory cytokine expression in macrophages[291]. This correlates
with PSG1s pro-inflammatory cytokine attenuation as demonstrated earlier in this thesis.
Integrins αVβ3 and αIIbβ3 have been implicated in interactions between platelets and
HUVEC cells [292]. Furthermore, as outlined earlier, leukocyte adhesion and transmigration
through the endothelium are critical steps in the inflammatory process in which integrins
play a fundamental role. In addition it has been demonstrated that integrin αV-specific
RGD mimetics attenuate mononuclear cell invasion into an allogenic renal graft model
[293]. Given PSG1s inhibitory function on platelet integrin, as well as evidence of the
association of PSG with the maternal vasculature in pregnancy [294] it is hypothesized that
PSG1 could also have a similar effect on this aspect of normal leukocyte biology by inhibiting
the interaction of leokocytes with endothelial cells.
4.2 Objectives and Outcomes
In generating my evidence supporting the existence of an interaction between the platelet
integrin αIIbβ3 and PSG1, a cell based Fluorescent Ligand Binding Assay was developed to
demonstrate affinity for integrinαIIbβ3 using stable empty vector transfected (Mock) control
cells and integrin over-expressing cells and fluorescently labelled PSG1. One objective of
this work was to determine if this assay could be modified to allow for the detection of
endogenous PSG binding using anti-PSG mAbs. It was shown that endogenous PSG from
pooled term pregnant plasma behaved similarly to recombinant PSG1 in this assay. In
addition, other RGD-recognising integrins were selected as candidate receptors for PSG1.
Integrin β3, αVβ3 andα5β1 over-expressing CHO cells were sourced and the over-expression
of integrins on these cells was characterised to determine their suitability for application to
the Fluorescent Ligand Binding Assay. Only integrin β3 CHO cells showed sufficient over-
expression of the respective integrin αVβ3 heterodimer to justify application to the assay
from which a trend for increased binding of PSG1 to integrin over-expressing cells was
observed. This assay was further supported by in vitro binding data demonstrating PSG1
interacting with integrinαVβ3 purified from placenta. In addition, the hypothesis that PSG1
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could affect monocyte-endothelial interactions was tested in a static fluorescent moncyte-
endothelial interaction assay but found to not have any affect.
4.3 Results
4.3.1 Development of a cell-based Fluorescent Ligand Binding Assay (FLBA)
During the investigations into the interaction between PSG and integrin αIIbβ3, a plate
based Fluorescent Ligand Binding Assay (FLBA) was developed to provide further evidence
in support of the interaction. Integrin αIIbβ3 over-expressing CHO-K1 cells (a kind gift
from Prof. Niamh Moran, Molecular and Cellular Therapeutics, Royal College of Surgeons
in Ireland) were enriched by FACS to select for highly over-expressing cells relative to the
empty vector transfected mock control cells. The cell sorted integrin over-expressing cells
showed an approximate 100 fold enrichment of the integrin αIIbβ3 relative to the mock
control cells (Fig. 4.1(A)). Though these cells were over-expressing the integrin, this over-
expression dropped when cells were routinely maintained in culture, requiring periodic
enriching of the cells by FACS. These cells were seeded and fluorescently labelled PSG1800
was incubated with the cells and the plate processed as outlined in the materials and
methods. Figure 4.1(B) shows fluorescent PSG1 binding to enriched integrin αIIbβ3 over-
expressing cells and mock controls, as well as SYTO60®nucleic acid staining acquired on an
Odyssey infrared imaging system. Densitometric analysis of this staining, when normalised
to nucleic acid stain, shows a greater than 50% increase in binding of fluorescent PSG1 to
integrinαIIbβ3 over-expressing cells relative to the mock control cells confirming the in vitro
binding data (Fig. 4.1(C)) [180].
With a goal of adapting the FLBA for the examination of endogenous PSG binding, the
assay was modified to optimise detection of the binding of PSG1 by monoclonal antibodies
against PSG, which we are characterising, namely mouse anti-PSG1 mAb5 (a kind gift
from Stepan Jonjic, Croatia). The mAb binding was detected using a fluorescently labelled
secondary antibody. Cell density was again controlled for using the SYTO60®nucleic acid
stain. Figure 4.2(A) shows a representative Indirect Fluorescent Ligand Binding Assay
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(iFLBA) image. When images were quantified and normalised to nucleic acid stain the iFLBA
detects a greater than 50% increase in PSG1 binding to the integrin αIIbβ3 over-expressing
cells (Fig. 4.2(B)). Thus a cell-based assay system for PSG-binding has been developed
which can be applied to see if a similar increased binding to integrin αIIbβ3 over-expressing
cells by PSG from plasma samples of pregnant women can be detected.
Plasma samples from 6 pregnant women at term were mixed and applied to the assay in
quadruplicate. Figure 4.3(A) shows a representative iFLBA. A greater than two-fold increase
in PSG binding to integrin over-expressing cells versus mock controls was detected using
the plasma samples (Fig. 4.3(A)). This indicates that endogenous PSG appears to have a
similar affinity for platelet integrin αIIbβ3 supporting published work [180]. Non-pregnant
sample controls proved toxic to cells and so were not investigated further.
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Figure 4.1: Fluorescently labelled PSG1800 shows increased binding to integrinαIIbβ3 dual
overexpressing CHO-K1 cells in Fluorescent-Ligand Binding Assay (FLBA)
(A) Empty vector transfected mock control cells and αIIbβ3 dual over-expressing CHO-K1
cells were incubated with fluorescently labelled anti-CD41 antibody and highly expressing
cells were selected by FACS for propagation and subsequent experimentation. (B)
Representative image of PFA-fixed CHO-K1 cells incubated with PSG1800 and stained with
SYTO60®nucleic acid stain and (C) quantification of PSG1800 binding normalized to nucleic
acid stain. n=5, students t-test.
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Figure 4.2: PSG specific mouse monoclonal detects increased PSG1 binding in Indirect
FLBA
(A) Representative image showing increased binding of PSG1 to αIIbβ3 dual over-expressing
CHO-K1 cells over empty vector transfected Mock control with SYTO60®nucleic acid stain
to control for cell number. (B) Graph of mean fluorescent intensity showing this difference
is significant, p< 0.05, students t-test, n=3.
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Figure 4.3: Endogenous PSG shows increased binding to α I Ibβ3 dual over-expressing
CHO-K1 cells in anti-PSG mAb LBA
(A) Representative image showing increased binding of edogenous PSG from maternal
plasma to αIIbβ3 dual over-expressing CHO-K1 cells over empty vector transfected Mock
control cells with SYTO60®nucleic acid stain to control for cell number. (B) Graph of mean
fluorescent intensity showing this difference is significant, p< 0.05, students t-test, n=3.
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4.3.2 PSG1 binds integrinαVβ3
As part of the research into whether RGD-recognising integrins could serve as receptors
for PSG1, a number of functional blocking experiments were carried out to examine
whether integrin αVβ3 and αMβ2 blockade of the THP-1 monocytic cell line could affect
PSG1 induction of TGF-β1. However, given the subsequent finding that latent TGF-β1
contaminates recombinant PSG1 generated for this study and that SEC purified PSG1 did
not induce TGF-β1 release, these data have not been included. Investigations into candidate
integrinα5β1 were carried out on over-expressing cells (a kind gift from Prof. Errki Ruoslahti,
Sandford Burnham Medical Research Institute, La Jolla, CA, USA). Empty vector transfected
Mock control and over-expressing cells were screened for over-expression to ascertain
suitability for application to the iFLBA. However these cells proved negative for integrin
over-expression as determined by FACS meaning no population of enriched integrin over-
expressing cells could be isolated for further studyFigure 4.4.
The identification of a β3 integrin containing binding partner for PSG1 led us to hypothesize
that other β3 integrins might represent binding partners for PSG, mediating known
immunomodulatory properties or, given the anti-thrombotic role underpinned by the PSG-
platelet integrin interaction, novel anti-adhesive or anti-migratory functions for PSGs. To
that end integrin β3 over-expressing and integrin αVβ3 dual over-expressing cells as well
as mock controls were obtained (a kind gift from Prof. Yoshikazu Takada, Department of
Dermatology, UCDavis, California, USA) and assayed by FACScan for over-expression of
the β3 subunit and αVβ3 heterodimer respectively, using β3specific and αVβ3 heterodimer
specific antibodies. Figure 4.5(A) shows that the β3 integrin over-expressing cells were
positive for the β3 subunit and that this subunit was contained in similar levels of αVβ3
heterodimer. The αVβ3 dual over-expressing cells did not stain positively. The β3 CHO
cells were applied to the iFLBA. The integrin over-expressing cells were enriched for FACS
using an APC-labelled anti CD51 antibody and applied to the iFLBA. Figure 4.5(B) shows
a representative iFLBA image. Figure 4.5(C) demonstrates that PSG1 shows a trend of
increased binding to the β3 CHO cells over mock controls.
The next step was to confirm the interaction between these two proteins biochemically.
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Integrin αVβ3 purified from human placenta was purchased to carry out in vitro binding
assays with PSG1 as has been demonstrated for integrin αIIbβ3 [180]. Briefly, purified
integrin was immunoprecipitated as outlined in the Materials and Methods chapter
section 2.13. Protein G bound integrin was then re-suspended in buffer with 2µg of PSG1 for
1 hr at room temperature. Protein bound beads were recovered boiled and analysed by SDS
PAGE and western immunoblot for integrin and PSG1. Figure 4.6 shows that, as previously
identified, PSG1 interacts with integrin αIIbβ3 and the integrin αVβ3, confirming the earlier
iFLBA result with the β3 CHO cells. Following the confirmation of this interaction by iFLBA
and by the in vitro binding assay, it was aimed to investigate whether blocking the integrin
would alter the affinity of PSG1 for circulating blood cells.
To identify whether blocking of integrins negatively affected PSG1 affinity to monocytes.
A preparation of peripheral blood mononuclear cells isolated by Ficoll-Hypaque density
gradient centrifugation were incubated with blocking antibodies against integrins αVβ3
and another important integrin on monocytes and macrophages, αMβ2. PBMCs were
subsequently incubated with fluorescently labelled PSG1488 and anti-CD14 antibody. After
washing, multi-channel FACS analysis was used to examine whether integrin blockade had
any affect on PSG1488 affinity for CD14+ gated monocytes. Figure 4.7(A) shows the staining
of CD14+ monoctes with fluorescent PSG1. From the mean fluorescent intensity graph it
can be seen that blockade of integrins αVβ3 or αMβ2 had no affect on PSG1488 binding to
cells.
A large body of evidence has been gathered implicating a role for HSPGs as mediators of
attachment of PSGs to the surface of cells. The affinity of two murine PSGs for several HSPGs
was investigated by Sulkowski and colleagues [171]. The authors demonstrated that PSGs
17 and 23 shared an interaction with HSPGs but that only PSG17 bound to the tetraspanin
CD9. Lisboa and colleagues demonstrated that the presence of glycosaminoglycans on the
cell surface is required for PSG1 attachment and further demonstrated that transfection
of cells deficient in condroitin and herparan sulphate, with Syndecans 1-4 and glypican-1,
increased binding of PSG1 the authors also demonstrated that PSG1-induced tubleogenesis
is dependant on the interaction of PSG1 with cell surface proteoglycans[170]. Subsequently
Blois and collegues demonstrated PSG22 binding to heparan sulphate chains of syndecans
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[156]. Consequently, the effect of heparin and heperan sulphate on fluorescent PSG1
binding to a monocytic cell line was investigated. Figure 4.8 shows that both heparin
and heperan sulphate inhibit the interaction between fluorescent PSG1488 and the THP-1
monocytic cell line. This confirms the previous findings that cell surface proteoglycans are
significant mediators of the attachment of PSG1 to the cell surface. As such it is unlikely that
integrin blockade would affect the affinity of PSG1 for the cell surface.
Figure 4.4: Integrin α5β1 cells are negative for the integrin
Empty vector Mock control cells and integrin α5β1 over-expressing cells were stained with
anti-integrin α5β1 antibody and FITC-labelled secondary before being analyzed by FACS.
The α5β1 cells appeared to have lost over-expression of the α5β1 integrin.
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Figure 4.5: PSG1 binding to integrinαVβ3 cannot be detected by indirect FLBA
(A) Integrin αVβ3 and β3 over-expressing CHO cell lines as well as mock controls were
examined for expression of β3 and αVβ3 by FACS with antibodies that distinguish the
individual β3 and αVβ3 heterodimer molecules. β3 CHO cells stain positive with both
antibodies but αVβ3 CHO cells showed no over-expression compared to controls. (B)
Application of mock and β3 CHO cells to indirect FLBA could not detect significantly
increased PSG1 binding to β3 over-expressing CHO cells versus control though a trend of
increased binding was present.
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Figure 4.6: PSG1 interacts with purified integrins α I Ibβ3 and αVβ3 in vitro in a protein
pull down assay
Immunoblots of immunoprecipitations showing PSG1 pulls down with integrins αIIbβ3 and
αVβ3 in solution. Work of Pat Kiely, University of Limerick, Ireland.
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Blocking antibodies do not affect PSG1-488 binding
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Figure 4.7: Anti integrin αVβ3 and αMβ2 blocking antibodies do not affect PSG1488
binding to primary monocytes
(A) Representative FACS staining of CD14+ gated cells for PSG1488 binding in presence of
integrin blocking antibodies. (B) Graphical representation of MFI of n = 3 from 3 seperate
donors showing integrin blocking antibodies have no effect on PSG1488 binding, n=3.
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Figure 4.8: Heparin and heperan sulphate block PSG1488 binding to THP-1 monocytic cell
line
(A) Representative FACS staining of THP-1 cells for PSG1488 binding in presence of indicated
concentrations of heperin and heperan sulphate. (B) Graphical representation of MFI of
PSG1488 binding. One-way ANOVA, n=3.
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4.3.3 PSG1 and endothelial interactions
The final stage of this body of work was to determine if a novel functional role for
the interaction between PSG1 and integrins could be determined. Given the nature of
integrins as adhesion molecules and furthermore given the published function of PSG as
an inhibitor of integrin αIIbβ3, taken with the notably high levels of PSG in circulation, it
was decided to investigate whether PSG1 affected the attachment of monocytes to TNF-
α-activated endothelium. This physiological processes represents a critical step in the
process of inflammation and as targeting this could significantly attenuate the immune
response it is considered a good candidate for investigating in the context of potential PSG
functions in pregnancy. Figure 4.9 (A) shows representative false coloured ImageJ analysed
immunofluorescence images of wells with fluorescently labelled monocytes adhered to
HUVEC-2 endothelial cells for the indicated times and with the indicated treatments.
Densitometric analysis reveals that PSG1 has no significant effect on monocyte adhesion
Fig. 4.9 (B).
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Figure 4.9: PSG1 attenuates monocyte attachment to activated enodothelium
(A) Representative Image-J output, false-coloured images from analysis of one replicate of
endothelial attachment assay. (B) Graphical representation of measurment of pixel area of
fluorescent THP-1 attachment to endothelial cells, n=3.
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4.4 Discussion
The identification of the intergrin αIIbβ3 as a binding partner for PSG demonstrated a
novel anti-platelet function for these hormones [180]. In this chapter the published
assay demonstrating increased binding of fluorescent PSG1 to integrin over-expressing
cells was modified allowing for the confirmation of this interaction with endogenous
PSG as detected by anti-PSG monoclonal antibody. To further extend this assay format,
several stable integrin over-expressing cells were sourced and screened for over-expression
of the respective integrins. When tested, integrin α5β1 and αVβ3 over-expressing cells
were negative for integrin over-expression. Integrin β3 CHO cells tested positive for αVβ3
heterodimer over-expression and were enriched and applied to the modified iFLBA. This
identified a second potential integrin binding partner for PSG1 as the assay detected a trend
for increased PSG1 binding to the β3 CHO cells versus mock controls. While the assay
did not give a statisitically significant result, it is believed that this is likely due to the low
level of integrin over-expression in comparison to the integrin αIIBβ3 CHO cells. These
cells showed an almost 100-fold increase in expression while the β3 CHO cells showed <
10 fold over-expression. A major difficulty found in utilising stably over-expressing cell
lines is the cumulative loss of expression from these cells over time, leading to a need for
continual enrichment through FACS. Moreover, significant differences in the quality of the
cells used makes accurate comparisons difficult. It is felt that a switch to a transient dual
over-expression system might yield better results for the type of assays utilised here.
However, to verify the integrin αVβ3 assay biochemically, purified integrin αVβ3 from
placenta was incubated with PSG1 in an in vitro binding assay. This confirmed the earlier
identified interaction with platlet integrin αIIbβ3 and further confirmed the iFLBA result
with the β3 CHo cells. Thus a novel integrin binding partner for PSG1 has been identified
in the integrin αVβ3, mediating an as yet unknown function. As already outlined functional
blocking experiments were carried out with anti-αVβ3 blocking antibody LM609 on THP-1
cells to investigate whether this antibody could block PSG1 induced cytokine release. The
data proved negative, however no conclusions could be drawn from the data due to the
earlier described contaminating latent TGF-β1. This contamination has been published and
it was shown that TGF-β1-free PSG1 immunomodulatoy effects were still TGF-β1 dependant
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based on a novel cell-free ability of PSG1 to activate latent TGF-β1 [260], though earlier
work in this thesis appears to contradict this. While not investigated in this body of work,
RGD tri-peptides have been shown to attenuate the ability of integrin αVβ3 to potentiate
the inflammatory response of macrophages to LPS and TNF-α[291]. It is possible that
PSG1 treatment has a similar effect on αVβ3 integrin and inflammation. This evidence
is in agreement with the earlier pro-inflammatory cytokine attenuation observed in this
thesis. The application of a PSG1N KGD→AAA mutant to the in vitro binding assay would
elucidate whether, as is the case with integrin αIIbβ3, integrin αVβ3 binds PSG1 in an KGD-
independent manner. This requires further investigation. Moreover, the possibility that
PSG1 binds other RGD recognising intgrins such as α5β1 and αMβ2 cannot be ruled out.
In addition, if PSG1 is found to bind multiple integrins, it is possible that some integrin
interactions may prove to be KGD-dependant.
Investigations into the affinity of fluorescently labelled PSG1 for CD14+ primary monocytes
showed that blocking antibodies had no effect on PSG1 cell surface binding. However, as
outlined, several publications have shown HSPGs such as Syndecans and Glypican-1 to
be important mediators of the binding of PSGs to the cell surface. In agreement we this
we demonstrated that soluble heparin and heperan sulphate blocked PSG1488 binding to
moncytic THP-1 cells.
To investigate the hypothesis that, based on the identified inhibitory effect of PSG1 on
platelet integrin αIIbβ3, PSG1 could play a role in attenuating inflammation through
affecting the activities of integrins involved in the process of recruitment of leukocytes to
sites of inflammation, we performed a static fluorescent leukocyte-endothelial adhesion
assay. The data demonstrate that PSG1 did not negatively impact on the attachment
of monocytic THP-1 cells to TNF-α activated HUVEC-2 cells. While the preliminary
investigations into this area have proved negative, more refined approaches may yet yield
a result. Moreover, potential roles for PSG in altering vascular permeability and leukocyte
transmigration were not investigated due to time constraints and represent interesting areas
for continued research. Importantly RGDS peptides have been demonstrated to not exhibit
anti-adhesive effects on HUVEC cells seeded on collagen IV, however the did attenuate
FGF-2 mediated chemotaxis [295]. Moreover, a role for integrin αVβ3 ligand vitronectin in
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vascular permeabilty has recently been identified lending further support to the hypothesis
that PSG1, an integrin αVβ3 ligand, requires investigation in these types of assays [296].
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Chapter 5
Conservation of Function in Novel
Horse PSG-like CEACAM49
5.1 Introduction
As highlighted in the introduction PSGs are found in higher primates and rodents and
their proposed immunological, angiogenic and haemostatic functions imply fundamental
roles in the haemochorial placental phenotype common to these two orders of mammals.
PSG genes are, however, also found in bats and horses [58]. In bats there is evidence of
invasive haemochorial placentation in many species, therefore presence of PSG genes in
this order correlates with the invasive haemochorial phenotype [297]. However, in horses
this correlation breaks down somewhat as they do not posses a haemochorial placental
phenotype, rather, an epitheliochorial one. Interestingly, the horse placenta does possess
unique highly invasive, immunoreactive, trophoblastic structures that exist for a limited
period during gestation, the endometrial cups. These are small, 1-10 cm long structures
composed of invasive trophoblasts that form in the early stages of equine placentation [298].
Following the arrest of the equine blastocyst in the uterus due to its dramatically increasing
size and a concomitant increase in uterine tone, the girdle of proliferative trophoblast cells
on the conceptus are directly apposed to the maternal epitelium. These are the source of
the endometrial cup cells. They digest through the maternal basement membrane and
117
5. CONSERVATION OF FUNCTION IN NOVEL HORSE
PSG-LIKE CEACAM49 5.1 Introduction
establish themselves in the maternal tissue, progressively invading maternal uterine glands.
They are the source of equine CG [299, 300]. The cells of the endometrial cups induce a
strong innate and cell mediated immune response from the mother, eventually leading to
destruction of the cups 2-3 months into gestation, which normally lasts approximately 360
days. A correlation has been observed between the stage of the developing trophoblast cup
cells and the maternal immune response [301]. There is an initial strong response that is
reduced between days 45 and 60 which subsequently increases again following this stage,
where the leukocytes are seen to invade from the peripherary and base of the cups, where
they have been accumulating, and begin actively destroying the necrotic cup tissue. The
other changes involved in the early stages of horse placentation that ultimately lead to the
extensive non-invasive microcotyledonary endotheliochorial placenta, but which are not
directly related to the biology of the trophoblast, are reviewed extensively in [302].
Adams and colleagues utilised a skin allo/auto-graft experiment in mares followed by
mating with the stallion allograft donors to the, now, immunologically primed mares, to
demonstrate the assymetric immune response observed between the endometrial cups
and the circulating immune system during equine pregnancy [303]. The development
of strong humoral antibody responses, in first and second pregnancies in primed mares,
or in second pregnancies in un-primed mares, was not concurrent with a strong cellular
immune response in the endometrial cups. Early invasive chorionic girdle cells in the horse,
as distinct from other species, express high levels of paternal MHC antigens, [304, 305].
These are down-regulated during differentiation into the endometrial cup cell lineage
[306]. However, the short-term expression of MHC is sufficient to induce an early and
stronger maternal anti-MHC response in horses than in any other species examined [307].
Thus factors inherent to the endometrial cups are attenuating the maternal immune
response to the cup tissue for the duration of the cups in pregnancy. Flaminio and
colleagues demonstrated that isolated invasive trophoblastic cup cells can reduce lyphocyte
proliferation and alter expression of cytokine mRNA such as IFNgamma [308]. Analysis of
the lymphocyte sub-populations in equine pregnancy confirmed this split immunological
tolerance between the peripheral blood lymphocytes and those at the maternal fetal
interface with higher levels of IFN-γ+ and FOXP3+ lymphocytes found in the populations
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from the endometrial cups [43]. In a further extension of this concept, ectopically
transplanted chorionic girdle cells were found to survive for a time period similar to that of
the endometrial cups in the mare while reproducing physiological changes associated with
pregnancy such as estrus suppression [309, 44]. This confirms the importance of innate
immunoregulatory functions of equine trophoblasts to their prolonged surivival.
Therefore, as pointed out by Kammerer and Zimmerman, the presence of PSGs in the
horse, while not adhering to the correlation between PSG and haemochorial placentation in
species, does still correlate with a local invasive trophoblastic phenotype[58]. Furthermore,
the immunological suppression associated with the cup environment, where the equine
PSG-like CEACAM expression is seen, is similar to the functions proposed to be carried
out by the PSGs in their sites of expression in other species. We hypothesised that horse
PSGs might function similarly to human and mouse PSGs in immunomodulatory and anti-
platelet assays. We therefor tested putative horse PSG CEACAM49 in assays examining these
functions.
5.2 Objectives and Outcomes
The putative equine PSG genes identified by Kammerer and Zimmerman were
supplemented with further genes identified by the author subsequent to publication [58].
Phylogenetic analysis of the horse CEA family confirmed the relationship between equine
CEACAM1 and the putative horse PSG genes. Furthermore, given the unique nature of
placentation in the horse and the distant nature of the relationship between it and other
mammals with PSGs, I looked for othologous relationships between the putatative horse
PSGs and the PSGs of other animals. No orthologous relationships were found. An
alignment of protein sequences of the horse PSGs leader sequences and N-domains with
human PSG1 leader sequence and N-domain was generated to illustrate sites of conserved
amino acids. To establish whether the putative equine PSGs are indeed functionally
equivalent to PSGs, a member of this family, CEACAM49, was cloned into a mammalian
expression system and protein was made to test in various assays where PSG function has
been explored earlier in this thesis. It was found that horse PSGs do not induce TGF-β1,
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however, and in contravention to the expected hypothesis given the epitheliochorial nature
of the equine interhaemal barrier, CEACAM49 did disrupt the human platelet-fibrinogen
interaction.
5.3 Results
Determining the relatedness of the horse putative PSGs to the horse CEACAM family
supports their identification as CEACAM1-related genes, as alignment and phylogentic
tree analysis follows the pattern outlined in [58] whereby the PSGs cannot be significantly
discriminated (50% cut-off) from a broad CEACAM1-like cluster (Fig. 5.1 (B)). Within the
CEACAM1-like cluster the putative PSG genes do not cluster together.
In order to determine whether any putative horse PSGs showed orthology to the PSGs in
other species, a pairwise alignment of the N-domains of available PSG sequences excluding
the leader sequence, in baboon, chimpanzee, human, mouse, rat and horse was carried out.
A phylogenetic tree generated using maximum parsimony was utilized to infer the closeness
of relatedness of the genes (Fig. 5.2). The tree reveals the previously reported orhtologous
relationship between some rodent PSGs (Williams, J., PhD thesis). The horse PSGs cluster
together indicating the lack of any orthologous relationships supporting the hypothesis
that these genes were likely an independent adaptation in the horse from a CEACAM1-like
ancestor common to all species examined.
Next, the horse putative PSGs were examined by aligning the protein sequences
encompassing the leader sequences and N domains against the leader sequence and N
domain of PSG1 (Fig. 5.3(A)). This allowed for the identification of conserved amino
acid sequences that may be critical to the structure and function of the horse proteins.
The sequences were analyzed by the Signal-P database to predict the cleavage site of the
leader peptide. The cleavage site for PSG1 was earlier identified by N-terminal protein
sequencing (Fig. 3.2). For most of the horse PSGs the software predicts cleavage after
amino acid 35, except in instances of a substitution at this site of a lysine (K) for a glutamine
(Q). Here the software predicts a more N-terminal cleavage site. There is considerable
variation in amino acid conservation around this site. Generation of the proteins and
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confirmation of the cleavage site by protein sequencing would be required to confirm these
data. Furthermore, horse PSGs show considerable variation in the solvent exposed F-G
loop where the conserved RGD like tri-peptide is located in primate and rodent N- and
N1-domains respectively. Horse PSGs do possess an RGD-like tri-peptide in the C-C’ loop.
However, based on homology modelling of human PSG1, this loop is not believed to be
as solvent exposed as the F-G loop in PSGs. The lysine (K34) of this loop is predicted to
be surrounded by residues of the C’ and E strands reducing its bioavailability (personal
communication, Dr. Rob Meijers, EMBL, Hamburg) (Fig. 5.3(B)). In human and mouse
PSGs these residues would be located in a difficult to access region of the proteins N- or
N1-domains that would require complex folding of the remaining PSGdomains for access
However, as the horse PSGs are only composed of N-domains access to these residues
is not restricted by other domains. There is also significant variation in the NetNglyc
database predicted glycosylation pattern of the horse PSGs. CEACAM49 has five predicted
glycosylation sites, while the remaining horse PSGs have between one and three sites.
To assay the functionality of the horse putative PSGs, CEACAM49 was subcloned from
pRcCMV-ecaCEACAM49 into the pTT3 expression vector incorporating an C-terminal V5-
6xHis tag as outlined in the materials and methods section. This allowed for the generation
of horse PSG-like CEACAM49 protein in the Freestyle™293 expression system. Figure
5.4(A) shows the chromatogram of the imidazole elutions from the CEACAM49 bound
beads. The elution pattern was further observed by coommassie staining of the indicated
fractions which had been seperated by 12% SDS PAGE (Fig. 5.4(B)). The indicated fractions
were pooled, concentrated and dialyzed and 2 µg of the resultant protein was separated
by 12% SDS PAGE and stained by coomassie. This showed that there were contaminating
high molecular weight bands. To remove these the protein was further purified by SEC.
Figure 5.5(A) shows the chromatogram from application of the affinity purified CEACAM49
to an Superdex 200 prep grade column in PBS. The indicated fractions were pooled and
concentrated. The resultant protein along with the pre-SEC starting material was separated
by 12% SDS PAGE and stained with Gel Code Blue stain reagent (Fig. 5.5(B)). This
showed that the SEC effectively removed the contaminating proteins. Furthermore, as
TGF-β1 was identified as a contaminant of PSG preperations, the starting material and SEC
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purified CEACAM49 were tested for TGF-β1 contamination. Figure 5.5(C) shows that SEC
efficiently removed the contaminating TGF-β1 from CEACAM49. It was then investigated
whether, as published for PSG from other species, CEACAM49 could induce TGF-β1 release
from two previously reported PSG-responsive cell types. Figure 5.5(D) and (E) show that
24 hr treatment of human monocytic THP-1 cells and HUVEC-2 endothelial cell lines
with CEACAM49 did not induce TGF-β1 release relative to untreated, PBS and CEACAM1
controls. This is in keeping with earlier findings that PSG1 does not induce the release of
this cytokine from these cell lines.
To test the hypothesis that due to the physiology of the horse placenta and the possibility
that the endometrial cups contact the maternal blood before their destruction three
months into gestation, that the horse PSGs might exhibit the ability to inhibit the platelet-
fibrinogen interaction, the CEACAM49 protein was applied to a fluorescent fibrinogen-
platelet interaction assay as described in the materials and methods and in [180]. The result
showed that CEACAM49 inhibited the interaction in a dose dependant manner similar to
PSG1. Figure 5.6(A) shows the FACS graph for the 200 µg/ml treatment with PSG1 and
CEACAM49. Figure5.6(B) is a graphical representation of the fluorescent fibrinogen binding
as a percentage of the activated platelet sample showing the dose response.
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CEACAM1-like
A
B
Figure 5.1: Horse PSG-like CEACAMs cluster with CEACAM1-like horse CEACAMs
(A) Bootstrapped minimum parsimony tree of equine CEACAM N-domain sequences from
[58] shows horse PSGs (in red) do not cluster together on an individual branch. (B)
Allowing for a 50% confidence cut-off shows that horse PSG-like CEACAMs cluster with other
CEACAM1-like horse CEACAMs supporting their identification as CEACAM1-like genes.
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Figure 5.2: Horse PSG-like CEACAMs do not have orthology with rodent or primate PSGs
Individual species PSGs or CEACAMs cluster together with high confidence with primates
on one arm and rodents and equine on the other. An orthologous relationship is highighted
as previously reported between mouse (Mmus) and rat (Rn). Chimp (Pt) is separated from
human (Hs) and baboon (Ph) with high confidence. The branching of human with baboon
is not significant.
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Figure 5.3: Sequence alignment of putative horse PSGs with human PSG1N domain
(A) Invariant residues are coloured orange, while physico-chemically conserved residues
(with no more than one exception) are coloured blue. (B) Homology model of PSG1 N-
domain generated by Rob Meijers (EMBL, Hamburg) from CEACAM1 crystal structure with
position of F-G loop and C-C’ loop residues highlighted to indicate predicted availability of
residues on PSG N-domains.
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Figure 5.4: Purification of recombinant CEACAM49
(A) Chromatogram of 1.5 ml washes and imidazole elutions of CEACAM49 from nickel
agarose affinity column. (B) Coomassie stain of 22.5 µl of highlighted fractions separated
by 12 % SDS-PAGE. (C) Coomassie stain of 2 µg of CEACAM49 resulting from processing of
fractions.
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Figure 5.5: CC49 does not induce TGF-β1 release from human cell lines
(A) Chromatogram from CC49 applied to a Superdex 200 prep grade size exclusion column
with red box indicating area of interest from which fractions were pooled and concentrated.
(B) Coomassie stained 12% polyacrylymide gel with 8 µg of indicated protein per lane. (C)
TGF-β1 ELISA indicating that SEC removed latent TGF-β1 contaminant. SEC purified CC49
does not induce TGFβ1 release from HUVEC-2 endothelial cells, n = 3 (D) or THP-1 cells, n
= 3 (E). SM, Starting Material.
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Figure 5.6: Equine PSG-like CEACAM49 causes dose dependent inhibition of platelet-
fibrinogen interaction
(A) FACS showing fluorescent Oregon Green Fibrinogen binding to resting, TRAP-activated
and 200 µg/ml PSG1 and CEACAM49 pre-treated and TRAP activated human platelets. (B)
Graphical representation of dose dependent inhibition of OgFg binding to activated human
platelets, relative to untreated control, by PSG1 and CEACAM49. n = 3, One way ANOVA.
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5.4 Discussion
No orthologous relationship could be identified for the horse PSG-like CEACAMs
confirming their likely independent evolution from a horse CEACAM1-like ancestor rather
than a common PSG-like ancestor. The horse PSG-like CEACAMs are very different from
PSGs in other species being composed solely of a single IgV-like N-domain. Furthermore,
there is significant variation in predicted glycosylation site number between the family
members, much more than is evident in the N- or N1-domains of primate and rodent PSGs
respectively. This variation could reflect a diversification in function among horse PSG-
family members.
Consistent with the earlier findings for PSG1, there is no TGF-β1 induction from the cell
types tested following 24 hr CEACAM49 treatment. There were detectable levels of TGF-
β1 present in the preparations of the protein pre-SEC. This is relevant due to the recently
proposed association of PSG1 with TGF-β1 [260]. However as the Ni-NTA beads have
also been demonstrated to bind the latent TGF-β1 particle, it is not possible to determine
if a specific association of TGF-β1 with CEACAM49 occurs [265, 260]. Furthermore,
the presence of high molecular weight contaminants which could be carriers of TGF-β1
similarly confounds this. It is also possible that the horse protein may not be able to react in
a cross species manner in this assay due to differences between species receptors. Critically,
without access to a horse cell type of relevance and a horse TGF-β1 ELISA, it is not possible
to conclusively rule out the potential for TGF-β1 induction from horse PSGs-like CEACAMs.
TGF-β1s’ functions in immune regulation, especially in the regulation of T-cell activity,
make it an excellent candidate for further investigations of the function of horse PSG-like
CEACAMs.
While not examined further in this work, it is most likely that the horse PSGs have important
roles in T-cell regulation, given the large cell mediated response from the maternal immune
system but the delayed destruction of the endometrial cup structures in horse pregnancies.
It is clear that factors inherent to the invasive equine trophoblast alter the maternal
cell mediated immune response. Evidence that in vitro co-culture model of invasive
horse trophoblast cells and peripheral blood lymphocytes has an inhibitory effect on the
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proliferative capacity and cytokine expression pattern of the lymphocytes [308], as well
as the earlier cited studies demonstrating the asymmetric immunological response to
ectopically transplanted invasive trophoblst and the endometrial cups, versus the systemic
immune system, clearly illustrate this. Evidence for the role of PSGs in T-cell function has
been increasing since it was identified in [170] that they bind CD4+ T-cells in a heperan
sulphate proteoglycan (HSPG) mediated fashion and since [157] demonstrated a role for
PSG1 in generating a Tr e g cell phenotype in vivo mediated by PSG1 treated dendritic
cells. This was further extended by evidence from [260] that showed PSG1 treated mice
have increased CD4+Foxp3+Latency Associated Particle-TGF-β1+ T-cells isolated from the
lamina propria of the gut which is TGF-β1 dependant.
The main functional evidence generated in this chapter was that CEACAM49, similar to
human and mouse PSG, exhibits the ability to inhibit the interaction between activated
platelets and fibrinogen. No investigations have yet looked for horse putative PSG
expression in the serum of pregnant mares due to technical constraints and the relatively
recent discovery of these genes. While no evidence of contact between the maternal blood
and the fetal tissue could be found in the literature, it is highly likely that horse PSGs will
still be present in the maternal blood, as one of the major secretions of endometrial cups
is choriogonadotrophin, which is found at very high levels in the maternal blood of the
pregnant mare while the cups persist. PSGs have been shown to bind other integrins,
besides platelet integrin and it is possible, though not investigated here, that this binding
also exists in horse PSGs. Significantly this work represents the first functional evidence
ascribing PSG-like properties to this family of proteins in the horse. Moreover, it shows that
potentially the anti-platlet properties of the PSGs are not strictly tied to the haemochorial
phenotype, an intriguing observation that could potentially widen the list of species in
which PSGs could potentially be found.
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Chapter 6
Discussion and Future Directions
The work contained in this thesis aimed to extend our understanding of PSG expression,
secretion, function and evolution by examining domains and motifs in PSG1 through
mutagenesis and functional experimentation, as well as investigating novel binding
partners and conservation of function in novel putative PSG genes in the horse. During the
course of the work a major confounding factor for much of the functional experiments with
the PSG1 mutants was discovered [265, 260] and confirmed. This raises questions not only
about some of the earlier work in this study but also much of the published work examining
proposed functions of PSGs as well as functional elements in PSG1 [153, 154, 158, 155, 170,
171, 156, 157]. In spite of this, several novel findings were successfully generated.
Firstly, a significant insight gained from the mutagenesis of N-glycoylation sites in PSG1N
was that the N61 site appears to make a greater contribution to the stability of this domain
than the other mutants. Moreover, introduction of this site into the PSG9N construct
rescued expression of this protein. The significance of this site to full length PSG function
was not confirmed due to the contamination by TGF-β1, however, its absence in half of
human PSGs, due to differences in the the amino acid at position 63, thus ablating the
glycosylation consensus sequence, is relevant. In addition, all human CEACAMs (bar
CEACAM16) as well as most mouse PSGs do not possess this consensus sequence which
would seem to imply that it is not essential for function. Production of PSG4 and PSG9
for this thesis, which both lack this sequence, gave lower yields when purified in a similar
131
6. DISCUSSION AND FUTURE DIRECTIONS
manner to PSG1. As such, an important future experiment would be to compare yield
of purified protein for PSG9 and a PSG9 P63T mutant. Importantly, PSG1 is the most
highly transcribed PSG at term in human pregnancy [180]. While no evidence yet exists
quantifying individual PSG levels in the blood during pregnancy, this might indicate PSG1
is highly expressed. Until the relative levels of PSGs in the blood during pregnancy are
determined it is not possible to make an estimation as to the importance to pregnancy
of PSGs containing the N61 glycosylation site compared to the remaining PSGs. In terms
of the retention/loss of this site in human PSGs over evolutionary time, it is possible that
selective disadvantage arising from decreases in the ability to secrete PSG proteins may be
counteracted by increased activity of these proteins resulting from conformational changes
due to the presence of a proline (P) or alanine (A) at position 63 in human PSG N domains.
This would make the absence of glycosylation at the N61 site neutral and could explain why
half of human PSGs do not possess this. This was not examined here. Further bioinformatic
and structural analysis of this site could yield interesting answers and provide intriguing
insights into the evolution of the human PSG gene family.
The immunomodulatory properties of PSG1 were examined in a screen of LPS-induced
cytokines. It was found that PSG1 attenuated LPS-induced Cxcl2 in a mouse macrophage
cell line. This effect was shown to not require the N domain. The panel of LPS-responsive
genes affected by PSG1 was expanded to include IL6 and TNFA, which were also confirmed
at the protein level in mouse primary BMDMs. IL-6 and IL-10 had been reported as being
induced by PSGs [149, 153, 157, 148], a result that could not be replicated here. Importantly,
these findings were potentially confounded by the earlier mentioned TGF-β1 contaminant.
It was noted however that active TGF-β1 was almost entirely absent in all tested preparations
of proteins used in this study. Nonetheless, to examine this an extra experiment examining
PSG1 attenuated pro-inflammatory cytokines was performed that included small molecule
inhibitors against TGF-βRI. The result could not identify any contribution by TGF-β1
signalling to PSG1s attenuation of pro-inflammatory cytokine signalling in monocytic THP-
1 cells. This was in contrast to the findings of [260] who showed that PSG1 attenuation
of IL-6, TNF-α and IFN-γ were TGF-β1 dependant in primary lymphocytes isolated from
the lamina propria of mice with DSS-induced colitis. This contradiction requires further
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investigation. The means by which PSG attenuates NFκB-regulated gene expression is still
not understood, though we have ruled out alterations in the pattern of IκBα degradation
as being responsible. In addition, inhibition of PKA signalling was also ruled out as a
mechanism underpinning PSG1s attenuation of LPS-induced pro-inflammatory cytokine
expression.
Though not examined here, it has been proposed that PSGs have an important role to play
in T-cell biology and the polarization of the immune system during pregnancy along the
recently called for, more sophicated Th1, Th2, Th17 and T regulatory cell spectrum [48, 169].
More refined immunological experimentation such as that utilised in [157] and [260] will
yield interesting data on the functions of PSGs in this area.
Taken together this work shows that much work of the published work into PSG function
and the elucidation of functionally important elements in PSG1 requires further analysis.
Future efforts in this area will require more stringent protocols for the generation of
recombinant PSG, incorporating multiple different forms of chromatography such as
tandem affinity and size exclusion chromatography, as was shown here. Many of the
mutants generated for this study were novel and as such of general value to the field. In
addition, the importance of the pattern of glycosylation modifications on the recombinant
proteins, though not investigated here, also needs to be addressed to allow for appropriate
studies of PSG function. Critically, the absence of a knock out mouse model for Psgs is one
of the main hurdles to furthering our understanding of the exact functional roles of these
hormones which still remains unknown.
The second main aim of this thesis was the investigation of PSG1 receptor identity. It
was known, and confirmed here, that HSPGs are the major mediators of PSG binding
at the cell surface. This is a pattern that is found in many growth factor cell surface
interactions. However, data showing that PSGs bind integrin αIIbβ3 mediating a novel
inhibitory function provided increasing evidence that PSG interaction with a different
integrin could be mediating the other reported functions of the protein. PSGs have a
conserved RGD-like tri-peptide on a solvent exposed loop in their N and N1 domains in
human and mouse [81]. Thus RGD-recognising αMβ2, α5β1 and αVβ3 were selected as good
candidates for investigation as potential PSG1 receptors. Moreover these integrins are found
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on cell types that PSG are regularly in contact with such as endothelial, trophoblastic, and
leukocytic [243, 207, 51, 310, 311]. Functional experiments with blocking antibodies against
integrins αMβ2 and αVβ3 were negative and also confounded by the TGF-β1 contaminant
and so not included here. In addition, plans at examining integrin α5β1 binding to PSG1
by means of the iFLBA could not be attempted as the over-expressing cell line proved
negative. However, data was generated showing increased binding of PSG1 to β3 CHO
cells which was subsequently supported by in vitro binding data. Thus a novel integrin
binding partner had been identified mediating an as yet unknown function. Given the
important roles that integrins play in the recruitment of leukocytes to sites of inflammation
[184], I investigated whether PSG1 could affect this process in a static fluorescent leukocyte-
endothelial adhesion assay. It was found that PSG1 had no effect on the adhesion of
leukocytes in this assay. This finding represents a preliminary investigation into a complex
and developing area of immune research. Further experimentation would be required to
rule out a role for PSG in this process. It was aimed to examine leukocyte transmigration
through endothelial layers in a transwell experiment but time constraints prevented this.
There remains interesting observations to be made in this area. Moreover, an inhibitory
function of PSG on leukocyte invasion makes sense in the environment in which they are
found during pregnancy.
Finally, a recently identified group of CEACAM genes in the horse showed an expression
pattern that indicated they may in fact represent PSG genes [58]. We investigated the
relationship of these genes within the horse CEA family as well as their relationship with
PSG genes from primates and rodents. We confirmed the identification of the genes as
CEACAM1 related and moreover showed that no orthologous relationship exists between
the horse putative PSGs and those of other primate and rodent species examined. This
showed that the genes were evolved from a CEACAM1 like ancestor as well as the likelihood
that they arose independently in the horse lineage. The presence of PSGs in the horse
does not correlate with haemochorial placentation which is seen in all species in which
PSGs have been found to date. It does however correlate with an invasive trophoblast
phenotype that is unique to the horse among epitheliochorial mammals [58]. As such, I
investigated whether horse CEACAM49 possessed immunomodulatory properties or anti-
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platelet functions found in PSGs from human and mouse. Horse CEACAM49 was found
to not induce TGF-β1 from human moncytic or endothelial cell lines. The horse PSG
was however found to posess anti-platelet properties, a fascinating finding given the
epitheliochorial nature of horse pregnancy. This would seem to imply that CEACAM 49 and
possibly other horse PSGs may have a role in haemostatic regulation during the early stages
of horse pregnancy while the endometrial cups persist. Though not investigated here it is
likely that horse putative PSGs play an important role in regulating T-cell function at the
materno-fetal interface as it has been demonstrated that there is a distinct population of
Treg like cells located at the maternal-fetal interface in the horse [43].
In summary, the findings of this thesis show that glycosylation plays an important role
in the expression of PSGs in the human and that the N61 glycosylation site in particular,
being absent in half of human PSGs, represents an intriguing site for investigating the forces
driving the evolution of the human PSG gene family. Furthermore, complications associated
with the identification of TGF-β1 as a contaminant of PSG from mammalian expression
systems requires that much PSG research into functional elements within PSG1 is revisited.
Further research is needed to elucidate the recently identified associated between PSG1
and latent TGF-β1 [260]. A novel integrin receptor for PSG1 has been identified mediating
an unknown function for these hormones. Investigations into whether PSG plays a role
in leukocyte adhesion and invasion during inflammation is expected to reveal interesting
findings in the future. Finally, horse PSG-like CEACAMs have been demonstrated to possess
PSG-like properties lending suport to them being PSGs opening upon chances for the
investigation of PSG biology in a species with a radically different type of placenta.
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7. APPENDIX
A
B
Figure 7.1: pTT3 and pTT3-B PSG1 vector maps
(A) Vector map of pTT3, a modified version of the pTT construct with an extended Multiple
Cloning Site (MCS). PSG1 was originally cloned into this vector as outlined in Shanley et al.
2013 [180] (B) pTT3 PSG1 was modified to introduce a HindIII site before the pBluescript
V5His sequence and to remove the EcoRI site 3’ of the insert sequence yielding pTT3-B PSG1
(Mrs Melanie Ball). This allowed cloning of other sequences into pTT3-B incorporating the
pBluescript V5His tag sequence.
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